预约演示
更新于：2026-04-03
Dapagliflozin
达格列净
更新于：2026-04-03
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、优先审评 (中国)、优先审评 (澳大利亚)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C24H35ClO9 |
InChIKeyGOADIQFWSVMMRJ-UPGAGZFNSA-N |
CAS号960404-48-2 |
关联
1,030
项与 达格列净 相关的临床试验RBR-6m2hb8h
Use of Dapagliflozin in adults patientes with Sickle Cell Disease
开始日期2027-01-01 |
申办/合作机构 |
NCT06560333
Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin
The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.
开始日期2026-11-30 |
申办/合作机构 |
NCT07056699
Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production in Type I Diabetic Patients
Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future.
In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the Dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with Type 1 Diabetes (T1D).
In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the Dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with Type 1 Diabetes (T1D).
开始日期2026-07-15 |
100 项与 达格列净 相关的临床结果
登录后查看更多信息
100 项与 达格列净 相关的转化医学
登录后查看更多信息
100 项与 达格列净 相关的专利（医药）
登录后查看更多信息
3,421
项与 达格列净 相关的文献（医药）2026-12-01·JOURNAL OF MOLECULAR MEDICINE-JMM
Dapagliflozin inhibits TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration
Article
作者: Kameshima, Satoshi ; Sakai, Kosei ; Sato, Remi
Abstract:
Myxomatous mitral valve (MV) disease (MMVD) is a common cardiac condition in humans and dogs. Currently, no therapeutic agent is available for MMVD that can prevent MV degeneration. Transforming growth factor (TGF)-β-induced transdifferentiation of valvular interstitial cells (VICs) is a key process in MV degeneration. Dapagliflozin is used to treat type 2 diabetes, and it alleviates cardiac and renal fibrosis by inhibiting the TGF-β signaling pathway. In this study, we investigated the effect of dapagliflozin on TGF-β-induced transdifferentiation of VICs and MV degeneration in rats. Protein expression levels and contractile forces generated by VICs were determined using western blotting and a collagen gel contraction assay, respectively. Structural changes of the MV were detected using histological staining. Dapagliflozin inhibited TGF-β-induced Smad2/3 phosphorylation and increased alpha-smooth muscle actin expression and the cellular contractile force. In contrast, dapagliflozin increased the activity of adenosine monophosphate-activated protein kinase (AMPK)α. However, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, an AMPK activator, inhibited TGF-β-induced Smad2/3 phosphorylation. AMPKα gene knockdown impeded the inhibitory effect exerted by dapagliflozin on TGF-β-induced Smad2 phosphorylation. Additionally, dapagliflozin increased AMPKα phosphorylation and suppressed TGF-β-induced MV degeneration, alpha-smooth muscle actin expression, and Smad2/3 phosphorylation in isolated rat MV. To the best of our knowledge, this study is the first to demonstrate that dapagliflozin inhibits TGF-β-induced VIC differentiation and subsequent MV degeneration by suppressing Smad signaling via AMPK activation, suggesting that dapagliflozin is a potential novel therapeutic agent for MMVD.
Key messages:
TGF-β-induced VIC differentiation leads to MV degeneration.DAPA, an SGLT2 inhibitor, suppresses the TGF-β signaling pathway.DAPA inhibits TGF-β-induced differentiation of rat VIC via AMPK activation.DAPA inhibits TGF-β-induced degeneration and signal transduction in isolated rat MV.DAPA suppresses MV degeneration by inhibiting VIC differentiation.
2026-12-01·MOLECULAR BIOLOGY REPORTS
Dapagliflozin attenuates hypothyroidism induced liver and lung dysfunction via regulation of mitophagy and apoptosis
Article
作者: Ahmed, Manar Fouad ; Mohammed, Marwa Abdeltawab ; Eweda, Sarah A ; Ali, Esraa Mohamed ; Abdelrahim, Dina Sayed ; Mohammed, Maha Tarek
BACKGROUND:
Thyroid hormones are mainly concerning with regulation of organs metabolism. Hypothyroidism is a pathological condition characterized by decrease of T3 and T4 level that negatively impact various organs especially liver and lung. Dapagliflozin (DAPA) is an anti diabetic drug posses antioxidant and anti apoptotic properties AIM OF THE STUDY: The aim of this work is to identify the effect of DAPA on disturbance of liver and lung functions result from hypothyroidism MATERIALS AND METHODS: Twenty four rats (6 rats/group) were divided into four groups: control group, DAPA group that received DAPA (1 mg/kg/day for five weeks), PTU group that received propylthiouracil (15 mg/kg/day for five weeks), PTU+ DAPA group that received PTU and DAPA as described in the other groups RESULTS: Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect CONCLUSION: DAPA protects against liver and lung injury result from hypothyroidism.
2026-06-01·International journal of cardiology. Cardiovascular risk and prevention
Renal and cardiovascular effects of SGLT2 inhibitors among hypertensive patients with chronic kidney disease: A systematic review and meta-analysis
Review
作者: Danny, Siska Suridanda ; Kuncoro, Brm Ario Suryo ; Amalia, Fauqi ; Kosen, Yosua Darmadi ; Pintaningrum, Yusra ; Dharma, Ahmad Surya ; Javier, R Mohamad ; Faizin, Iqbal ; Fiohana, Puput ; Nurpradika, Brianka Yudha ; Firasghani, Muhammad Almy ; Kurniawan, Kristian ; Puspitasari, Renny Anggraeni ; Andiani ; Samudra, Dian
Background:
Chronic kidney disease (CKD) is frequently complicated by hypertension, a dual contributor to disease progression and cardiovascular risk. Despite standard therapy with renin-angiotensin-aldosterone system inhibitors, residual risk remains high. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapy with proven renal and cardiovascular benefits, but their effects in hypertensive CKD patients remain less well defined.
Methods:
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that evaluated SGLT2 inhibitors in CKD patients with baseline systolic blood pressure ≥140 mmHg or renovascular disease. PubMed, Embase, and Cochrane Library were searched from inception to August 2024. Eligible RCTs compared an SGLT2 inhibitor versus placebo and reported outcomes in hypertensive subgroups. Primary outcome was a composite of kidney failure, sustained decline in estimated glomerular filtration rate (eGFR ≥40-50 %), or cardiovascular death. Secondary outcomes included kidney-specific endpoints, cardiovascular composite outcomes, and serious adverse events (SAEs). Pooled odds ratios (ORs) were calculated using random-effects models.
Results:
Three RCTs were included: CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin), and EMPA-KIDNEY (empagliflozin), encompassing 5436 hypertensive participants. For the primary outcome, SGLT2 inhibitors reduced risk compared with placebo (OR 0.76, 95 % CI 0.65-0.88). Kidney outcomes showed consistent benefit (OR 0.70, 95 % CI 0.58-0.85). Cardiovascular events were modestly reduced (OR 0.79, 95 % CI 0.64-0.97). SAEs were slightly lower with SGLT2 inhibitors (OR 0.85, 95 % CI 0.74-0.96). Overall certainty of evidence was graded as moderate.
Conclusions:
Among hypertensive patients with CKD, SGLT2 inhibitors significantly reduce renal disease progression and cardiovascular events while maintaining favorable safety. These findings support their integration into standard therapy for this high-risk population.
1,892
项与 达格列净 相关的新闻（医药）2026-04-02
·米内网
精彩内容
近期，糖尿病用药（化+生，下同）新品捷报频传。北京双鹭药业的西格列汀二甲双胍片(Ⅰ)/(Ⅱ)、正大天晴药业集团的恩格列净二甲双胍缓释片(Ⅳ)等先后获批。今年以来，糖尿病用药已有28个品种（55个受理号）获批上市。米内网数据显示，糖尿病用药在2025年Q1-Q3中国零售药店终端销售额同比增长14.67%。从TOP20品牌来看，2大超10亿品牌领跑，4个国产品牌上榜。截至目前，糖尿病用药1类新药有5个品种（15个受理号）报产在审，其中，江苏恒瑞医药的舒地胰岛素诺利糖肽注射液、深圳君圣泰生物的熊去氧胆小檗碱胶囊均在今年报产。
畅销糖尿病药国产第2家诞生，东阳光药、先为达亮眼
日前，国家药监局官网显示，北京双鹭药业的西格列汀二甲双胍片(Ⅰ)/(Ⅱ)获批上市。在此之前，安徽金太阳生化药业的吡格列酮二甲双胍片(15mg/500mg)、北京圣永制药的二甲双胍恩格列净片(Ⅰ)、湖南华纳大药厂的二甲双胍恩格列净片(Ⅴ)、正大天晴药业集团的恩格列净二甲双胍缓释片(Ⅳ)、云鹏医药集团的二甲双胍恩格列净片(Ⅰ)、湖南迪诺制药的磷酸西格列汀片、辽宁鑫善源药业的达格列净片同日获批。
今年以来糖尿病用药（化+生）新药获批情况
来源：米内网中国申报进度（MED）数据库
今年以来，糖尿病用药（化+生）已有28个品种（55个受理号）获批上市，其中，3个为新药，宜昌东阳光长江药业的奥洛格列净胶囊、杭州先为达生物的埃诺格鲁肽注射液为1类新药，珠海联邦生物医药的德谷胰岛素注射液为国产第2家。
珠海联邦生物医药的德谷胰岛素注射液用于成人糖尿病的治疗，可单独使用或与口服降糖药、餐时胰岛素联合用药，全面满足临床长期血糖管理需求。联邦制药表示，此次获批是公司在糖尿病领域实现关键技术突破的又一重要成果。未来，将持续致力于新产品研发，并重点提升在生物医药行业的竞争力及创造力，深耕慢病治疗领域，以更优质的产品、更完善的管线服务临床、惠及患者。3月25日，联邦制药再传捷报，其全资附属公司联邦生物科技自主研发的1类创新药UBT251注射液已完成在中国2型糖尿病患者中的II期临床研究。
奥洛格列净胶囊是东阳光药自主研发的1类创新药，用于单药或联合二甲双胍改善成人2型糖尿病患者的血糖控制。东阳光药表示，此次新品获批将进一步丰富集团在糖尿病产品线的布局，集团将依托成熟的生产体系与营销网络，快速推进该产品的商业化落地，同时持续开展该产品在糖尿病并发症等领域的临床探索，进一步拓展适应症范围，为糖尿病患者提供更全面的治疗解决方案。截至目前，东阳光药在糖尿病用药领域拥有18款产品生产批文。
埃诺格鲁肽注射液是先为达生物自主研发的1类创新药，今年1月获批上市，用于成人2型糖尿病患者的血糖控制，是全球首个获批上市的cAMP偏向型GLP-1受体激动剂。3月，埃诺格鲁肽注射液新适应症获批，用于在控制饮食和增加体力活动基础上对成人超重/肥胖患者的长期体重管理，这标志着该药物已完成减重与2型糖尿病双适应症的布局。资料显示，先为达生物建立以核心资产（埃诺格鲁肽注射液等）为基石的强大产品管线，拥有偏向型激动剂发现平台、口服肽给药平台、半衰期延长平台，并基于这三大核心技术平台确立一系列候选药物，构建覆盖GLP-1及其协同机制的全面的产品管线，为代谢性疾病患者提供注射和口服等可持续且高质量的治疗方案。
2大超10亿品牌领跑，扬子江、甘李、华领上榜
近年中国零售药店终端糖尿病用药（化+生）销售情况（单位：万元）
来源：米内网格局数据库
米内网数据显示，糖尿病用药（化+生）在近年中国零售药店（城市实体药店+网上药店）终端销售规模持续扩容，2025年Q1-Q3同比增长14.67%。其中，城市实体药店是主力销售渠道；网上药店则保持快速增长，2025年Q1-Q3销售额已接近2024年全年。
从治疗小类来看，GLP-1受体激动剂（化+生）、SGLT2抑制剂（化）、胰岛素及其类似药（化+生）位居前三，合计市场份额占比超过50%。从增速来看，GLP-1受体激动剂（化+生）最快，其次是口服降糖药复方（化），增速均超过30%。从剂型来看，片剂和注射剂为两大主流剂型，合计市场份额占比超过95%。从在销品种数量来看，涉及150个产品，超过700个品牌。
2025年Q1-Q3中国零售药店终端糖尿病用药（化+生）一级集团TOP10
来源：米内网格局数据库
集团TOP20中，跨国药企依旧占据前列，诺和诺德、阿斯利康、默克、默沙东、礼来位居前五，前十仅有远大健康和扬子江药业2家国内药企上榜。此外，多家国内药企表现亮眼，恒瑞医药凭借超过200%增速晋身集团TOP20，远大健康、甘李药业、华领医药、正大制药等均有双位数增速。
2025Q1-Q3中国零售药店终端糖尿病用药（化+生）品牌TOP20
来源：米内网格局数据库
注：增长率低于10%用*表示
品牌TOP20中，诺和诺德的司美格鲁肽注射液和阿斯利康的达格列净片销售额均超10亿元，礼来的替尔泊肽注射液挺进TOP4品牌；4个国产品牌上榜，杭州中美华东制药的吡格列酮二甲双胍片(15mg/500mg)、扬子江南京海陵药业的依帕司他片销售额均超过2亿元，华领医药(上海)的多格列艾汀片、甘李药业的甘精胰岛素注射液增速均超过20%。
正增长品牌中，诺和诺德的司美格鲁肽注射液、默克的盐酸二甲双胍片、默沙东的西格列汀二甲双胍片(Ⅱ)、诺和诺德的德谷胰岛素利拉鲁肽注射液等均有双位数增速。
从集团层面来看，诺和诺德最多，有7个品种上榜，默沙东和赛诺菲各有2个品种上榜。
近年中国零售药店终端司美格鲁肽注射液销售情况（单位：万元）
来源：米内网格局数据库
司美格鲁肽注射液在2024年中国零售药店终端销售额首次突破20亿元大关，2025年Q1-Q3同比增长10.23%，是糖尿病用药（化+生）TOP1产品。日前，司美格鲁肽在中国核心化合物专利到期，意味着国内药企将加速入场。目前国内仅诺和诺德拥有生产批文，杭州九源基因、石药百克(山东)生物制药、惠升生物制药等10家国内企业报产在审，太极集团重庆涪陵制药、山东新时代药业、海南中和药业等超过20家国内企业获批临床。4月1日，成都倍特生物制药的司美格鲁肽注射液再有10个受理号报产获CDE受理。
近年中国零售药店终端多格列艾汀片销售情况（单位：万元）
来源：米内网格局数据库
多格列艾汀片是华领医药(上海)研发的1类新药，用于改善成人2型糖尿病患者的血糖控制。该产品在近年中国零售药店终端销售规模快速扩容，2023年销售额突破1亿元大关，2024年-2025年Q1-Q3同比增长均超过20%，成为糖尿病用药（化+生）TOP18品牌。不久前，华领医药发布公告，其全球首创新药葡萄糖激酶启动剂（GKA）多格列艾汀已获中国香港特别行政区政府卫生署药物办公室批准上市。公司表示，此次获批不仅为香港2型糖尿病患者带来全新治疗选择，更标志着公司以香港为枢纽，从中国正式进军东南亚及全球市场的战略布局已迈出关键一步。
重磅新品不断！恒瑞、君圣泰1类新药来袭
今年3月糖尿病用药（化+生）产品报产在审情况
来源：米内网中国申报进度（MED）数据库
在刚过去的3月，南通联亚药业的利格列汀二甲双胍缓释片、烟台鲁银药业的达格列净二甲双胍缓释片(Ⅰ)、安徽万邦医药科技的氢溴酸替格列汀片等多个糖尿病用药报产获CDE受理。其中，江苏恒瑞医药的舒地胰岛素诺利糖肽注射液、深圳君圣泰生物的熊去氧胆小檗碱胶囊2个为1类新药，而深圳君圣泰生物的熊去氧胆小檗碱胶囊则是公司提交的首个新药上市申请。
来源：米内网项目进度数据库
截至目前，糖尿病用药（化+生）1类新药有5个品种（15个受理号）报产在审，其中，恒瑞医药最多，有舒地胰岛素诺利糖肽注射液、HRS9531注射液、舒地胰岛素注射液3个品种报产在审。
资料来源：米内网数据库、公司公告等
注：米内网《中国城市实体药店药品终端竞争格局》，统计范围是：全国地级及以上城市实体药店，不含县乡村药店；《中国网上药店药品终端竞争格局》，统计范围是：全国网上药店所有药品数据，包括天猫、京东等第三方平台及私域平台上所有网上药店药品数据；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！
免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。
本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092
【分享、点赞、在看】点一点不失联哦
上市批准
2026-04-02
BMC Medicine [Jour] AND 24[volume] AND 1[issue]
生物医学中心 - 医学 24卷 1期
https://link.springer.com/journal/12916/volumes-and-issues/24-1
188 articles in this issue
Effectiveness of group-based art interventions for late-life depression: a systematic review and meta-analysis of randomized controlled trials
团体艺术干预对老年抑郁症的疗效：一项针对随机对照试验的系统综述和荟萃分析
Mohamad AzhdarlooRaziyeh AtaeiAbouzar Nazari
Research 24 February 2026
Article: 188
The associations of consultant sex on herding‑like prescribing behaviour: evidence from a web-based experiment with female primary care physicians in England
顾问性别对从众式处方行为的影响：来自一项针对英格兰女性初级保健医生的网络实验的证据
Sandro Tiziano StoffelMatthias SchwenkglenksBerna Cennet Özdemir
Research 24 February 2026
Article: 187
Tricarboxylic acid cycle metabolite index predicts adverse outcomes in acute myocardial infarction patients
三羧酸循环代谢物指数预测急性心肌梗死患者的不良预后
Ye WangPengyan WuBo Yu
Research 24 February 2026
Article: 186
Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids
靶向癌症干细胞可预测腹水来源的卵巢癌类器官的反应并逆转化疗耐药性
Xiaoli ZhangWen ZhangHuiqin Guo
Research 24 February 2026
Article: 185
Neural vulnerability to stress in adolescents: a longitudinal study using polyconnectomic scoring of depression risk
青少年神经对压力的易感性：一项使用抑郁风险多连接组评分进行的纵向研究
Yuan LiuMeijuan LiJie Li
Research 24 February 2026
Article: 184
Part of 1 collection:Child and adolescent psychiatry
所属专题合集：儿童与青少年精神病学
Classification of ALS molecular subtypes: a literature review on machine learning applications and their clinical value
肌萎缩侧索硬化症分子亚型分类：机器学习应用及其临床价值的文献综述
John K. JammalEsteban A. GomezAlfredo Iacoangeli
Review 23 February 2026
Article: 183
Part of 1 collection:Amyotrophic lateral sclerosis: latest advances and novel updates
所属专题合集：肌萎缩侧索硬化症：最新进展与新动态
Can we protect refugee children from mental health problems?— a scoping review of modifiable factors to inform preventive interventions
我们能否保护难民儿童免受心理健康问题困扰？——一项旨在为预防性干预提供信息的可改变因素的范围性综述
Rita GonçalvesM J MarquesSónia Dias
Research 23 February 2026
Article: 182
Part of 1 collection:Child and adolescent psychiatry
所属专题合集：儿童与青少年精神病学
The Trial Bank initiative to promote trustworthy living evidence for medication safety (PROMISE) of children: design and pilot validation
促进儿童用药安全可信实时证据（PROMISE）的试验库计划：设计与初步验证
Chang XuSuhail A. DoiPROMISE Collaborative Research Network
Research 21 February 2026
Article: 181
Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania
液体活检是否为诊断坦桑尼亚儿童和青年成人伯基特淋巴瘤的一种具有成本效益的方法？一项卫生经济学评估
Jingjing JiangLiz MorrellAI-REAL Consortium
Research 21 February 2026
Article: 180
The influence of immunohistochemistry-based subtypes on overall survival in breast cancer spine metastases: a systematic review and meta-analysis
基于免疫组织化学的亚型对乳腺癌脊柱转移总生存期的影响：一项系统综述和荟萃分析
Fon-Yih TsuangYun-Heng LiChung Liang Chai
Research 21 February 2026
Article: 179
Prenatal exposure to maternal asthma and asthma medication and neurodevelopmental outcomes: a population cohort study of 179,024 children
产前接触母体哮喘及哮喘药物与神经发育结局的关系：一项针对179,024例儿童的人群队列研究
Lama A. ShakhshirSarjit SinghMichael Fleming
Research 20 February 2026
Article: 178
First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC
T3011（一种表达IL-12和PD-1抗体的溶瘤性单纯疱疹病毒）首次人体1/2a期研究：通过瘤内（IT）注射作为单一疗法治疗包括复发或转移性头颈部鳞状细胞癌在内的晚期实体瘤
Dongmei JiWenmin FuXichun Hu
Research 20 February 2026
Article: 177
Expanding access to cerebrovascular imaging with routine MRI for pre-surgical assessment of intracranial tumor patients: an AI model development and multi-center validation study
利用常规MRI扩大脑血管成像在颅内肿瘤患者术前评估中的应用范围：一项人工智能模型开发与多中心验证研究
Chaoyue ChenZhouyang HuangJianguo Xu
Research 20 February 2026
Article: 176
Changing landscape of physical fitness and urban–rural inequalities: evidence from 1.2 million children and adolescents over 20 years of urbanization
20年城市化进程中120万例儿童和青少年体质健康状况及城乡差异的变化
Shan CaiJiaxin LiYi Song
Research 19 February 2026
Article: 175
Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis
抗糖尿病前期药物在糖尿病前期患者中的疗效和安全性：一项贝叶斯网状荟萃分析
Yike WuZihan WangGuo Ma
Research 19 February 2026
Article: 174
Clonal haematopoiesis of indeterminate potential and risk of incident psychiatric disorders
Yuefeng YuChenyi WanNingjian Wang
意义未明的克隆性造血与新发精神障碍风险
Research 18 February 2026
Article: 173
Spatial characterization of intrahepatic fat deposition across steatotic liver disease subcategories: a multicenter study
脂肪性肝病各亚类中肝内脂肪沉积的空间特征：一项多中心研究
Yan-Ci ZhaoMin WangFeng Chen
Research 18 February 2026
Article: 172
Pregnancy outcomes among medically complex populations with high risk of pregnancy mortality in Virginia: a retrospective observational study
弗吉尼亚州妊娠死亡高风险医学复杂人群的妊娠结局：一项回顾性观察研究
Michael J. GreenLauren G. AndersonJonas J. Swartz
Research 18 February 2026
Article: 171
Maternal amino acid metabolites during pregnancy and preterm birth: results from two prospective cohort studies
孕期母体氨基酸代谢物与早产的关系：两项前瞻性队列研究的结果
Jingnan ChenYidan DongJu-Sheng Zheng
Research 18 February 2026
Article: 170
Correction: Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications
更正：停用抗肥胖药物后体重的变化轨迹
Han WuWenjia YangLinong Ji
Correction 25 March 2026
Article: 169
Physical activity patterns and cardiovascular disease risk in adults with overweight or obesity: a prospective cohort study
超重或肥胖成人身体活动模式与心血管疾病风险：一项前瞻性队列研究
Kai MuYanan QiaoBo Xi
Research 16 February 2026
Article: 168
Part of 1 collection:Weight loss interventions and their health impacts
所属专题合集：减肥干预措施及其对健康的影响
Maternal migraine and offspring ADHD: triangulating the evidence
母亲偏头痛与后代多动症（ADHD）：多方证据综合分析
Yaxin LuoChristina DardaniEvie Stergiakouli
Research 14 February 2026
Article: 167
Part of 1 collection:Child and adolescent psychiatry
所属专题合集：儿童与青少年精神病学
An autonomous siRNA delivery system targeting NLRP3: implications in Parkinson’s disease
靶向NLRP3的自主性小干扰RNA（siRNA）递送系统：在帕金森病中的潜在意义
Lishan LinZhizong LiZhong Pei
Research 12 February 2026
Article: 166
Lay descriptions of painful temporomandibular disorders—an international consensus proposal for Global Burden of Disease estimates
颞下颌关节紊乱病疼痛的通俗描述——全球疾病负担评估的国际共识提案
A. LövgrenP. LivP. Svensson
Research 17 March 2026
Article: 165
Association of soluble tumor necrosis factor receptor 1 with tau pathology, brain atrophy, and cognitive decline: a longitudinal study
可溶性肿瘤坏死因子受体1与tau蛋白病变、脑萎缩及认知功能下降的关联：一项纵向研究
Yutong ZhangLulu SunAlzheimer’s Disease Neuroimaging Initiative
Research 11 February 2026
Article: 164
Part of 1 collection:Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题合集：健康老龄化与长寿：预防医学和风险因素的作用
Particulate matter and respiratory health in middle-aged and older adults: disentangling size-fractionated and constituent-specific effects under China’s clean-air policies
颗粒物与中老年人呼吸系统健康的关系：厘清中国净化空气政策下不同粒径及成分的特定影响
Yujing ChenZhaoyan LiuYu-ming Chen
Research 11 February 2026
Article: 163
Part of 1 collection:Climate change and human health
所属专题合集：气候变化与人类健康
Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands
荷兰为婴儿和青少年接种针对侵袭性脑膜炎球菌B病的疫苗的临床影响和成本效益
Thomas OttenMirjam KnolAnneke Steens
Research 10 February 2026
Article: 162
Association between trajectories of sleep quality and postpartum depression: a group-based trajectory model and computer-simulated network analysis
睡眠质量轨迹与产后抑郁之间的关联：基于组别的轨迹模型和计算机模拟网络分析
Xiaoxiao MeiJinzhou YuZengjie Ye
Research 10 February 2026
Article: 161
Part of 1 collection:Sleep and mental health
所属专题合集：睡眠与心理健康
Understanding Japan’s mortality advantage: a comparison of mortality in independent and dependent older adults in Japan and Sweden
解读日本在死亡率方面的优势：日本与瑞典独立生活及依赖他人生活老年人的死亡率比较
Shunsuke MurataMarcus EbelingKarin Modig
Research 23 March 2026
Article: 160
Part of 1 collection:Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题合集：健康老龄化与长寿：预防医学及风险因素的作用
The Young Adult Sleep model: an evolving causal loop diagram of mental health dynamics
青年睡眠模型：心理健康动态演变的因果环路图
Jeroen F. UlemanRushd F. M. Al-ShamaNaja Hulvej Rod
Research 16 March 2026
Article: 159
Part of 1 collection:Sleep and mental health
所属专题合集：睡眠与心理健康
Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma
基于抑瘤素M配体的CAR-T疗法对骨肉瘤显示出强大的抗肿瘤活性
Daniel FeinbergVinayak UppinReshmi Parameswaran
Research 17 March 2026
Article: 158
Antimicrobial catheters coated with poly-L-lysine for the prevention of bacteriuria in adults requiring short-term catheterization: a multicenter randomized controlled trial
涂有聚-L-赖氨酸的抗菌导管预防短期导尿成人患者菌尿症：一项多中心随机对照试验
Xinfei LiJun LiuKai Zhang
Research 09 February 2026
Article: 157
Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial
派安普利单抗联合来那度胺和R-GemOx方案（R2-GemOx-PD1i）治疗复发或难治性弥漫性大B细胞淋巴瘤：一项多中心、单臂、2期试验
Jin-Hua LiangTong-Yao XingWei Xu
Research 09 February 2026
Article: 156
Digital twin brain reveals state-specific stimulation targets for abnormal brain dynamics in tinnitus
数字孪生大脑揭示耳鸣异常脑动力学状态特异性刺激靶点
Jiaqi ZhangShuting HanTianzi Jiang
Research 10 February 2026
Article: 155
The case for mandatory reporting to enable targets for healthy and environmentally sustainable food: means, motive and opportunity
强制报告实现健康且环境可持续食物目标的理由：方法、动机和机会
Rachel PecheyLauren BandySusan A. Jebb
Debate 10 February 2026
Article: 154
Genetic insights into radiomic and proteomic changes under β1-blockers treatment in hypertensive heart disease and hypertrophic cardiomyopathy
β1受体阻滞剂治疗高血压性心脏病和肥厚型心肌病时放射组学和蛋白质组学变化的遗传学见解
Zhe ChenYifan TangKai Xie
Research 09 February 2026
Article: 153
Part of 1 collection:Cardiomyopathy and cardiac arrhythmias
所属专题合集：心肌病与心律失常
Optimizing drug-resistant tuberculosis diagnosis: cost-effectiveness of rapid molecular and phenotypic assays in South Africa
优化耐药结核病诊断：南非快速分子和表型检测方法的成本效益分析
Ginenus FekaduTadesse TolossaWai Kit Ming
Research 09 February 2026
Article: 152
Maternal smoking based on pre-birth health examination and risk of neurodevelopmental disorders in offspring: insights from a Korean mother–child cohort
基于产前健康检查探讨母亲吸烟与后代神经发育障碍风险的关系：来自韩国母婴队列研究的见解
Chan Soon ParkMoonyoung JangJun-Bean Park
Research 11 March 2026
Article: 151
Part of 1 collection:Child and adolescent psychiatry
所属专题合集：儿童与青少年精神病学
Effects of ablation versus drug therapy on clinical outcomes and quality of life by frailty status in atrial fibrillation: a post hoc analysis of the CABANA trial
根据衰弱状态分析消融术与药物治疗对心房颤动患者临床预后和生活质量的影响：CABANA试验的事后分析
Lili WangYanguang LiYunlong Wang
Research 07 February 2026
Article: 150
Part of 1 collection:Cardiomyopathy and cardiac arrhythmias
所属专题合集：心肌病与心律失常
Quantifying lifetime risk for 1,401 infectious diseases across the diabetes spectrum using a Bayesian approach
采用贝叶斯方法量化糖尿病全病程中1401种传染病的终生风险
Boomer B. OlsenMartin Tristani-FirouziEdgar Javier Hernandez
Research 07 February 2026
Article: 149
Part of 1 collection:Diabetes and infectious disease
所属专题合集：糖尿病与传染病
Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials
对接受生物制剂和JAK抑制剂治疗的特应性皮炎患者罹患哮喘和过敏性鼻炎的风险评估：一项针对随机对照试验的系统综述和网络荟萃分析
Liling ZengTong ZhouJing Li
Research 07 February 2026
Article: 148
Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma
布林西多福韦（brincidofovir）在外周T细胞和NK/T细胞淋巴瘤中的临床前活性
Jason Yongsheng ChanElizabeth Chun Yong LeeChoon Kiat Ong
Research 06 February 2026
Article: 147
Genetic risk factors modulate the association between physical activity and colorectal cancer
遗传风险因素调节身体活动与结直肠癌之间的关联
Anita R. PeoplesMireia Obón-SantacanaVictor Moreno
Research 05 February 2026
Article: 146
A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease
临床诊断阿尔茨海默病的疾病分期神经影像学标志物
Zhuangzhuang LiShaozhen YanYong Liu
Research 05 February 2026
Article: 145
Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation
胰高血糖素样肽-1（GLP-1）受体激动剂与糖尿病中疱疹风险的关联：一项目标试验模拟研究
Chi-Hsien HuangI-Hui ChiangJames Cheng-Chung Wei
Research 31 December 2025
Article: 144
Part of 1 collection:Diabetes and infectious disease
所属专题合集：糖尿病与感染性疾病
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial
局部晚期胃癌联合胸腺肽的新辅助免疫化疗：一项前瞻性临床试验
Hao XuFengyuan LiZekuan Xu
Research 26 February 2026
Article: 143
Part of 1 collection:Clinical trials for gastrointestinal cancer
所属专题合集：胃肠道癌症的临床试验
Detection of sequelae from acute meningitis during clinical review by a healthcare provider: a systematic review and meta-analysis
临床医生在临床复查中检测急性脑膜炎后遗症：一项系统综述和荟萃分析
Luisa F. AlvizCarla Y. KimKiran T. Thakur
Research 28 February 2026
Article: 142
Part of 1 collection:Acute meningitis: a collection of systematic reviews
所属专题合集：急性脑膜炎：系统综述合集
ISG15-driven immune modulation and tumor progression in breast cancer metastasis: insights from single-cell and spatial transcriptomics
ISG15驱动的免疫调节与乳腺癌转移中的肿瘤进展：来自单细胞和空间转录组学的见解
Hua ShaoHanlu TangYongqing Xu
Research 04 February 2026
Article: 141
Evaluating the impact of family history and polygenic risk scores on cardiometabolic disease risk
评估家族史和多基因风险评分对心代谢疾病风险的影响
Ebuka OnyenobiKnightess OyiboSally N. Adebamowo
Research 03 February 2026
Article: 140
Social networking site use, depressive and anxiety symptoms in adolescents: evidence from a longitudinal cohort study (SCAMP)
社交网站使用与青少年抑郁和焦虑症状：来自纵向队列研究（SCAMP）的证据
Chen ShenBraulio M. Girela-SerranoMireille B. Toledano
Research 03 February 2026
Article: 139
Part of 1 collection:Child and adolescent psychiatry
所属专题合集：儿童与青少年精神病学
Early gestational prediction of spontaneous preterm birth using a validated three-protein serum biomarker panel
使用经验证的三蛋白血清生物标志物组合进行早孕期自发性早产预测
Qiong LuoJuan WeiXuefeng B. Ling
Research 02 February 2026
Article: 138
Household cannabis cessation and adolescent mental health outcomes in a prospective cohort study
一项前瞻性队列研究中家庭大麻戒断与青少年心理健康预后的关系
Ming WangYixiang XuFei Li
Research 02 February 2026
Article: 137
Part of 1 collection: Psychoactives: Recreational drugs repurposed as novel therapies
所属专题合集：精神活性物质：娱乐性药物重新利用为新型疗法
Objective assessment of long-term impact of COVID-19 on multiple sensory functions
客观评估新冠肺炎对多种感觉功能的长期影响
Ahmad OdehVeronica L. FormanekKai Zhao
Research 27 February 2026
Article: 136
Detection of hearing loss by formal audiological testing after acute infectious meningitis: a global systematic review and meta-analysis
急性感染性脑膜炎后通过正式听力检测诊断听力损失：一项全球系统综述和荟萃分析
Luisa F. AlvizCarla Y. KimKiran T. Thakur
Review 28 February 2026
Article: 135
Part of 1 collection: Acute meningitis: a collection of systematic reviews
所属专题合集：急性脑膜炎：系统综述合集
Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities
血清学证据表明，居住在瑞典长期护理机构中的老年人存在沉重的呼吸道合胞病毒感染负担
Preeti MoarChristoffer GranvikMattias N. E. Forsell
Research 24 February 2026
Article: 134
Association of parental education with offspring psychiatric diagnoses, violent crimes, and suicidal behavior: a nationwide Swedish quasi-experimental study
父母受教育程度与后代精神疾病诊断、暴力犯罪和自杀行为之间的关联：一项瑞典全国范围的准实验研究
Mengping ZhouHenrik LarssonErik Pettersson
Research 26 February 2026
Article: 133
Discriminative performance of externally validated dementia risk prediction models: a systematic review and meta-analysis
外部验证的痴呆风险预测模型的鉴别性能：一项系统综述和荟萃分析
Blossom C. M. StephanJacob BrainMario Siervo
Research 02 February 2026
Article: 132
Part of 1 collection:Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题合集：健康老龄化与长寿：预防医学和风险因素的作用
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study
静脉注射大剂量硒预防铂敏感复发性卵巢癌化疗所致周围神经病变的有效性和安全性：一项3期、双盲、平行组、随机对照试点研究
Ga Won YimKyung Hee HanHee Seung Kim
Research 02 February 2026
Article: 131
Time for change in implementation research and practice
实施研究和实践中变革的时机已到
Mike EnglishJacob McKnightSebastian Fuller
Debate 02 February 2026
Article: 130
CardioMetAge estimates cardiometabolic aging and predicts disease outcomes
CardioMetAge可评估心脏代谢年龄并预测疾病结局
Yucan LiXinming XuKelin Xu
Research 31 January 2026
Article: 129
Disproportionate climate burden of rising temperatures on low birth weight in Pakistan
气温上升给巴基斯坦低出生体重儿带来的不成比例的气候负担
Syeda H. FatimaCorey J. A. BradshawZohra S. Lassi
Research 31 January 2026
Article: 128
Part of 1 collection: Climate change and human health
所属专题：气候变化与人类健康
Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy
利用靶向CD3ε、EpCaM和4-1BB的三特异性T细胞衔接器增强溶瘤病毒疗法：临床前评估及对癌症免疫疗法的启示
Zhongyi DongHaoyu ZhangZizhen Zhang
Research 30 January 2026
Article: 127
Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma
靶向降解BCL-XL与吉西他滨联用对胆管癌具有协同治疗作用
Qinghua ZengYan ZhangYonghan He
Research 30 January 2026
Article: 126
Association of DNA methylation with hypertension and blood pressure: a 7-year longitudinal study from KORA F4/FF4
DNA甲基化与高血压及血压的关联：来自KORA F4/FF4的7年纵向研究
Liye LaiAngelina Shin Yee JongMelanie Waldenberger
Research 04 February 2026
Article: 125
Shared genetic architecture of psychoactive substance use and pan-cancer: insights from a large‑scale genome‑wide cross‑trait analysis
精神活性物质使用与泛癌症的共享遗传结构：来自大规模全基因组跨性状分析的见解
Jiahang SongPengzhu LiOlivier Gires
Research 05 February 2026
Article: 124
Part of 1 collection: Psychoactives: Recreational drugs repurposed as novel therapies
所属专题：精神活性物质：作为新型疗法的娱乐性药物再利用
Intrauterine exposure to maternal diabetes and the risk of developing epilepsy in children: a national cohort study of 2.3 million children
宫内暴露于母体糖尿病与儿童患癫痫风险的关系：一项针对230万儿童的全国队列研究
Muhammad Zakir HossinMartina PerssonNeda Razaz
Research 14 February 2026
Article: 123
ADHD and adherence to antihypertensive medication treatment: a multinational cohort study
多动症与坚持抗高血压药物治疗的关系：一项多国队列研究
Honghui YaoYiling ZhouZheng Chang
Research 20 February 2026
Article: 122
How effective is rejoining a long-term weight loss program? The 5- and 10-year MRI-assessed Follow Interventions Trial (FIT) project
重新加入长期减肥计划的效果如何？5年和10年磁共振成像评估的随访干预试验（FIT）项目
Hadar KleinDafna PachterIris Shai
Research 30 January 2026
Article: 121
Part of 1 collection: Weight loss interventions and their health impacts
所属专题：减肥干预措施及其对健康的影响
Correction: Brain state dynamics and working memory in patients with schizophrenia and unaffected siblings
更正：精神分裂症患者及其未受影响兄弟姐妹的脑状态动态与工作记忆
Feiwen WangJie YangLena Palaniyappan
Correction 20 February 2026
Article: 120
Ocular light and optical radiation exposure as a modifiable environmental determinant of health: expert consensus on research gaps and priorities
作为可改变的环境健康决定因素的眼睛光暴露和光学辐射暴露：关于研究空白和优先事项的专家共识
Manuel SpitschanAnna M. BillerJohannes Zauner
Guideline 29 January 2026
Article: 119
Dietary patterns and neuropsychological function in adolescents: a cross-sectional and longitudinal study
青少年饮食模式与神经心理功能：一项横断面和纵向研究
Alexios ManidisNicolas Ayala-AldanaJordi Julvez
Research 29 January 2026
Article: 118
Part of 1 collection: Child and adolescent psychiatry
所属专题：儿童与青少年精神病学
Factors impacting the delivery of contextualized care in serious illness: a focus group study with healthcare professionals
影响危重症患者情境化护理实施的因素：一项针对医疗保健专业人员的焦点小组研究
Linda ModderkolkYvonne SchoonAnne B. Wichmann
Research 29 January 2026
Article: 117
Part of 1 collection: Palliative care and medicine
所属专题：姑息治疗与医学
Early interventions for first onset of symptoms of mental health conditions: an umbrella review of systematic reviews
针对心理健康问题首次出现症状的早期干预措施：一项系统综述的伞式评价
Jasmine LeePhoebe BarnettSonia Johnson
Research 29 January 2026
Article: 116
Harmonic patterns embedded in ictal EEG signals in focal epilepsy: new insight into the epileptogenic zone
局灶性癫痫发作间期脑电图信号中嵌入的谐波模式：对致痫区的新见解
Lingli HuLingqi YeShuang Wang
Research 28 January 2026
Article: 115
Part of 1 collection: Epilepsy: Seizure prevention, treatment, and epidemiology
所属专题合集：癫痫：发作预防、治疗和流行病学
Effects of aerobic or resistance exercise on sleep and cancer-related fatigue in patients with breast cancer during or after neoadjuvant chemotherapy: a 3-arm randomized controlled trial
有氧运动或抗阻运动对新辅助化疗期间或之后乳腺癌患者睡眠和癌症相关疲劳的影响：一项三臂随机对照试验
Alexander HaussmannMartina E. SchmidtKaren Steindorf
Research 28 January 2026
Article: 114
Neutrophil methylmalonic acid promotes microthrombus formation and adverse cardiac remodeling post-myocardial infarction through activating IL-6 signaling pathway-mediated NETosis
中性粒细胞甲基丙二酸通过激活IL-6信号通路介导的中性粒细胞胞外诱捕网形成（NETosis），促进心肌梗死后微血栓形成和不良心脏重构
Yige LiuJiaxin WangShaohong Fang
Research 28 January 2026
Article: 113
Statistical approaches to analyse the combined effect of seven air pollutants and breast cancer risk: a case–control study nested in the French E3N-Generations cohort
分析七种空气污染物联合作用与乳腺癌风险关系的统计方法：一项嵌套于法国E3N-Generations队列的病例对照研究
Camille GiampiccoloBéatrice FerversAmina Amadou
Research 28 January 2026
Article: 112
Part of 1 collection: Carcinogens and human health
所属专题合集：致癌物与人类健康
Is behaviour change communication guidance for general practice healthcare professionals evidence based? A systematic review
针对全科医疗保健专业人员的行为改变沟通指导是否具有循证依据？一项系统综述
Anika Schwarze-ChintapatlaJonathan Livingstone-BanksCharlotte Albury
Research 16 February 2026
Article: 111
Patient-centred postpartum care provision: virtual delivery, tiered escalation, and tensions between efficiency, preference, and clinical concern
以患者为中心的产后护理服务提供：虚拟服务模式、分级转诊机制，以及效率、患者偏好与临床关切之间的矛盾
Sergio A. SilverioJulia R. B. BrownEmma L. Duncan
Research 24 February 2026
Article: 110
Ethical dilemmas in climate change and healthcare delivery: a cross-sectional survey of US patient perspectives
气候变化与医疗服务中的伦理困境：一项针对美国患者观点的横断面调查
Andrew HantelEmily SenayGregory A. Abel
Research 27 January 2026
Article: 109
Part of 1 collection: Climate change and human health
所属专题：气候变化与人类健康
Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study
伊尼妥单抗联合卡瑞利珠单抗和优替德隆治疗既往接受过治疗的HER2阳性晚期乳腺癌：一项前瞻性、单臂、2期研究
Huimin LvTao SunMin Yan
Research 27 January 2026
Article: 108
Potential of earlier primary care health checks for prevention of cardiovascular events in younger age groups: population-based study in the United Kingdom
早期初级保健健康检查对预防年轻人群心血管事件的潜力：英国一项基于人群的研究
Catherine A. ScottLinxin LiPeter M. Rothwell
Research 24 January 2026
Article: 107
Comparative effects of salt substitutes on blood pressure, cardiovascular events and mortality: a systematic review and network meta-analysis
盐替代品对血压、心血管事件和死亡率影响的比较：一项系统综述和网络荟萃分析
Honghao LaiGihad NesrallahBradley C. Johnston
Research 23 January 2026
Article: 106
Association of short-term exposure to ambient air pollutants with liver function and mediation by fasting insulin: evidence from a rural cohort in China
短期暴露于环境空气污染物与肝功能的关系及空腹胰岛素的中介作用：来自中国农村队列研究的证据
Mengxin WangAogang ZhangWeidong Wu
Research 23 January 2026
Article: 105
Part of 1 collection:Climate change and human health
所属专题：气候变化与人类健康
Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial
辅助治疗：替雷利珠单抗、仑伐替尼和卡培他滨用于可切除的胆道癌：一项前瞻性II期试验
Yun FengNing ZhangLu Wang
Research 23 January 2026
Article: 104
Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study
袖状胃切除术与司美格鲁肽对减重及代谢结局的疗效比较：一项前瞻性非随机研究
Yutung YenQian ZhangYi Chen
Research 22 January 2026
Article: 103
Part of 1 collection:Weight loss interventions and their health impacts
所属专题：减重干预措施及其对健康的影响
Impact of sex on outcomes in patients treated with drug-coated balloons versus drug-eluting stents for de novo coronary artery lesions: Insights from the REC-CAGEFREE I trial
性别对接受药物涂层球囊与药物洗脱支架治疗的新发冠状动脉病变患者预后的影响：来自REC-CAGEFREE I试验的见解
Ping WangJingyu ZhouLing Tao
Research 22 January 2026
Article: 102
Assessing the comorbidity between asthma and depression through polygenic risk scoring and time-to-event models
通过多基因风险评分和时间事件模型评估哮喘与抑郁的共病情况
Xueting WangJun HeRenato Polimanti
Research 22 January 2026
Article: 101
Persistent immune, coagulation and cardiac dysregulation are correlated with later post-discharge mortality in children with severe malnutrition
严重营养不良儿童出院后持续存在的免疫、凝血和心脏功能失调与后期死亡率相关
Brenda KamauEvans O. MudiboJames M. Njunge
Research 22 January 2026
Article: 100
Correction: Computer assisted verbal autopsy: comparing large language models to physicians for assigning causes to 6939 deaths in Sierra Leone from 2019–2022
更正：计算机辅助口头尸检：对比大型语言模型与医生为2019 - 2022年塞拉利昂6939例死亡分配病因的情况
Richard WenAnteneh Tesfaye AssalifRashid Ansumana
Correction 14 February 2026
Article: 99
Characteristics of parks associated with depression in women only: a cross-sectional study of 329,363 adults
仅与女性抑郁相关的公园特征：一项针对329,363名成年人的横断面研究
Jonathan R. OlsenNatalie NichollsRichard Mitchell
Research 21 January 2026
Article: 98
Weight change mediates the effect of lifestyle intervention on postpartum diabetes in women with prior gestational diabetes: a secondary analysis of a randomized clinical trial
在生活方式干预对既往妊娠期糖尿病女性产后糖尿病影响中，体重变化的中介作用：一项随机临床试验的二次分析
Weiqin LiHuikun LiuGang Hu
Research 21 January 2026
Article: 97
Part of 1 collection: Diagnosis and management of gestational diabetes
所属专题：妊娠期糖尿病的诊断与治疗
Global drivers of heart failure attributable to atrial fibrillation/flutter: insights fromJoinpoint regression, age-period-cohort analysis, and future projections from the GBD 2021 Study
心房颤动/扑动所致心力衰竭的全球驱动因素：来自折点回归、年龄-时期-队列分析以及2021年GBD（全球疾病负担）研究未来预测的见解
Jing ChenZhu LiGregory Y. H. Lip
Research 20 January 2026
Article: 96
Part of 1 collection: Cardiomyopathy and cardiac arrhythmias
所属专题：心肌病与心律失常
Overdiagnosis of gestational diabetes mellitus during Ramadan: a retrospective population-based study in Catalonia, Spain
斋月期间妊娠期糖尿病的过度诊断：西班牙加泰罗尼亚地区一项基于人群的回顾性研究
Marta CarrascoBogdan VlachoMarta Hernández
Research 20 January 2026
Article: 95
Part of 1 collection: Diagnosis and management of gestational diabetes
所属专题：妊娠期糖尿病的诊断与管理
Why current risk factor-based approaches fall short in predicting stillbirth: a national cohort study of nulliparous women in England
为何当前基于风险因素的方法在预测死胎方面存在不足：英格兰初产妇全国队列研究
A. HowellB. ThilaganathanTommy’s National Centre for Maternity Improvement
Research 22 January 2026
Article: 94
Pay-it-forward intervention increased pneumococcal vaccine uptake among older adults in China: a randomized controlled trial
爱心传递干预措施提高了中国老年人肺炎球菌疫苗的接种率：一项随机对照试验
Jiao QinChunxing TaoBingyu Liang
Research 19 January 2026
Article: 93
The impact of e-cigarette taxation: a systematic review and meta-analysis on usage, pricing strategies, and public health implications
电子烟税收的影响：针对使用情况、定价策略和公共卫生影响开展的系统综述和荟萃分析
Quan WangZheng ZhuLi Yang
Research 17 January 2026
Article: 92
Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study
抗Claudin18.2×CD3双特异性抗体IBI389在实体瘤及胃或胃食管肿瘤患者中的安全性与初步疗效结果：一项1期剂量递增与扩展研究
Xiaoyu LiRuihong DaiFeng Bi
Research 16 January 2026
Article: 91
Part of 1 collection: Clinical trials for gastrointestinal cancer
所属专题：胃肠道癌症临床试验
Comparative risk of delirium among opioid users for non-cancer pain: a retrospective cohort study
比较非癌症疼痛使用阿片类药物者发生谵妄的风险：一项回顾性队列研究
Carlos Raul Ramirez MedinaMark LuntMeghna Jani
Research 31 January 2026
Article: 90
Association between preoperative interruption of antiplatelet therapy and postoperative thrombotic risk after minimally invasive surgery for abdominopelvic cancer in patients treated with P2Y12 inhibitors
接受P2Y12抑制剂治疗的患者行腹部盆腔癌症微创手术时，术前中断抗血小板治疗与术后血栓形成风险之间的关联
Masashi KubotaSatomi YoshidaKoji Kawakami
Research 16 January 2026
Article: 89
Comparative outcomes of distal ureterectomy vs. radical nephroureterectomy in high-risk distal ureteral urothelial carcinoma: a two-center cohort study in Northern and Southern China
高危远端输尿管尿路上皮癌患者行远端输尿管切除术与根治性肾输尿管切除术的疗效比较：中国北方和南方两家中心的队列研究
Junyi XieZhenhua LiuWei Yu
Research 16 January 2026
Article: 88
Co-occurrence patterns and related risk factors of dementia and Parkinson’s disease among older adults across 204 countries and territories: a spatial correspondence and systematic analysis
204个国家和地区老年人痴呆症与帕金森病共现模式及相关危险因素：空间对应与系统分析
Weiyang ChenMin DuJue Liu
Research 15 January 2026
Article: 87
Accelerated brain aging in amyotrophic lateral sclerosis and its prognostic associations: a cohort study
肌萎缩侧索硬化症加速脑衰老及其预后关联：一项队列研究
Chenhao FangJiaoting JinShuoqiu Gan
Research 15 January 2026
Article: 86
Part of 1 collection: Amyotrophic lateral sclerosis: latest advances and novel updates
所属专题：肌萎缩侧索硬化症：最新进展与新动态
The clinical effects and cortical mechanism of rTMS in poststroke lateropulsion: a randomized controlled trial
重复经颅磁刺激（rTMS）对脑卒中后侧方倾倒的临床效果及皮质机制：一项随机对照试验
Lijiao MengRaymond C. C. TsangQuan Wei
Research 14 January 2026
Article: 85
5-HT2C receptors in the glutamatergic neurons of dorsal raphe nucleus orchestrate the comorbidity of pain and anxiety in mice
中脑背侧缝际核谷氨酸能神经元中的5-HT2C受体调控小鼠疼痛与焦虑共病
Qi ZhangLi XieRiyue Jiang
Research 13 January 2026
Article: 84
The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome
POLE突变型结直肠癌的临床现状：一项现实结局的回顾性分析
Ting XuXuhui ZhangJian Li
Research 13 January 2026
Article: 83
The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial
度洛西汀治疗难治性慢性咳嗽的有效性和安全性：一项随机临床试验
Shengyuan WangHeng WuXianghuai Xu
Research 13 January 2026
Article: 82
Impact of diagnosis to ablation time on clinical outcomes in patients with atrial fibrillation: post hoc analysis of the CABANA trial
心房颤动患者从诊断到消融的时间对临床预后的影响：CABANA试验的事后分析
Manlin ZhaoYang ChenGregory Y. H. Lip
Research 12 January 2026
Article: 81
Part of 1 collection: Cardiomyopathy and cardiac arrhythmias
所属专题：心肌病与心律失常
Elevated maternal pre-transfer serum lipid peroxidation is associated with implantation failure and early pregnancy loss
母体转运前血清脂质过氧化水平升高与着床失败和早期流产相关
Zhangwei JiaJunxiang RenJunhao Yan
Research 12 January 2026
Article: 80
Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer
幽门螺杆菌感染对肠道和肿瘤内微生物组的影响及其与胃肠道癌症免疫治疗反应的关联
Keren JiaYang ChenLin Shen
Research 12 January 2026
Article: 79
Part of 1 collection: Gut microbiota: New treatments of human disease
所属专题：肠道微生物组：人类疾病的新疗法
SGLT-2 Inhibitor use and liver-related and mortality outcomes in patients with type 2 diabetes and compensated cirrhosis
SGLT-2抑制剂在2型糖尿病合并代偿性肝硬化患者中的应用及其对肝脏相关预后和死亡率的影响
Tien-Shin ChouDaniel Hsiang-Te TsaiEdward Chia-Cheng Lai
Research 12 January 2026
Article: 78
Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review
从试验外推至临床：基于系统综述构建预测模型，界定多发性硬化症疗法在现实人群中的获益边界
Bibiana BielekovaTianxia WuMichael Calcagni
Research 10 January 2026
Article: 77
A validated model for early prediction of group A streptococcal aetiology in necrotising soft tissue infections using minimal patient data
利用最少患者数据早期预测坏死性软组织感染A组链球菌病因的验证模型
Sonja KatzJaco SuijkerEdoardo Saccenti
Research 10 January 2026
Article: 76
Trends in lipid-lowering therapies in acute coronary syndromes after Chinese new insurance policy: a real-world analysis
中国新医保政策实施后急性冠状动脉综合征患者降脂治疗趋势：一项现实情况分析
Xin ZhaoShujing WuJunbo Ge
Research 09 January 2026
Article: 75
Fragmented healthcare and effective maternal coverage in Mexico, 2009–2023
2009-2023年墨西哥医疗体系碎片化与有效孕产妇医疗保障
Edson Serván-MoriDiego Cerecero-GarcíaOctavio Gómez-Dantés
Research 09 January 2026
Article: 74
Circadian rhythm disruption in cardiovascular disease: a systematic review and meta-analysis of mechanistic evidence from animal models
昼夜节律紊乱与心血管疾病：基于动物模型机制证据的系统综述与荟萃分析
Mrinal K. DasEvi De RyckJohanna Samulin Erdem
Research 09 January 2026
Article: 73
Frailty progression: The role of multimorbidity configurations in frailty transitions and predicting mortality risk among older adults
衰弱进展：多重共病组合模式在老年人衰弱状态转变及死亡风险预测中的作用
Rafael Ogaz-GonzálezQian ZouEva Corpeleijn
Research 08 January 2026
Article: 72
Part of 1 collection: Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题：健康老龄化与长寿：预防医学及风险因素的作用
Effect of probiotic supplementation on the gut microbiota diversity in healthy populations: a systematic review and meta-analysis of randomised controlled trials
益生菌补充剂对健康人群肠道微生物群多样性的影响：一项针对随机对照试验的系统综述和荟萃分析
Anna Júlia ÉliásKincső Csepke Földvári-NagyLászló Földvári-Nagy
Research 07 January 2026
Article: 71
Part of 1 collection: Gut microbiota: New treatments of human disease
所属专题：肠道微生物群：人类疾病的新疗法
Pain and high-impact pain in community-dwelling older adults in Australia and relation to sociodemographic and health-related factors, including physical disability, psychological distress, and quality of life
澳大利亚社区居住老年人的疼痛及重度疼痛情况，及其与社会人口统计学因素和健康相关因素（包括身体残疾、心理困扰和生活质量）的关系
Grace JoshySaman Khalatbari-SoltaniEmily Banks
Research 22 January 2026
Article: 70
Mortality and morbidity burden associated with smoking: evidence from a 1.6 million cohort in Hong Kong
与吸烟相关的死亡率和发病率负担：来自香港160万人队列研究的证据
Boyuan WangTingting ChenEric Yuk Fai Wan
Research 06 January 2026
Article: 69
Part of 1 collection:Carcinogens and human health
所属专题：致癌物与人类健康
Association between long-term extreme high temperature and mortality: a 9-million prospective cohort study
长期极端高温与死亡率之间的关系：一项900万人的前瞻性队列研究
Bo YinQi HuangKuiying Gu
Research 06 January 2026
Article: 68
Part of 1 collection:Climate change and human health
所属专题：气候变化与人类健康
Unraveling the neurotoxic mechanisms of tranexamic acid in epilepsy induction: a network toxicology and molecular docking approach
利用网络毒理学和分子对接方法揭示氨甲环酸诱发癫痫的神经毒性机制
Tianyang ChenDalong LiuXiangYang Leng
Research 03 January 2026
Article: 67
Part of 1 collection: Epilepsy: Seizure prevention, treatment, and epidemiology
所属专题：癫痫：癫痫发作的预防、治疗和流行病学
Trop2 immuno-PET/CT imaging of prostate cancer: a proof-of-concept translational study
Trop2免疫正电子发射断层扫描/计算机断层扫描（PET/CT）成像在前列腺癌中的应用：一项概念验证性转化研究
Xingru LongShuxian AnDawei Jiang
Research 31 December 2025
Article: 66
Methylmalonate accumulation contributes to myocardial vulnerability post-reperfusion: a novel therapeutic target and prognostic biomarker
甲基丙二酸蓄积促进再灌注后心肌脆弱性：一种新型治疗靶点和预后生物标志物
Shanjie WangJunChen GuoShaohong Fang
Research 31 December 2025
Article: 65
Prophylactic effect of intraoperative sodium oxybate on postoperative delirium in older patients undergoing major orthopedic surgery: a randomized clinical trial
术中羟丁酸钠对接受大型骨科手术的老年患者术后谵妄的预防作用：一项随机临床试验
Meiying CuiHang XuePing Zhao
Research 31 December 2025
Article: 64
Part of 1 collection:Psychoactives: Recreational drugs repurposed as novel therapies
所属专题：精神活性物质：将娱乐性药物重新用于新型疗法
Prevalence of hysterectomy in urban China and associations between metabolic disorders and hysterectomy: a multicenter population-based study involving over 9 million women
中国城市子宫切除术的流行情况以及代谢紊乱与子宫切除术之间的关系：一项涉及超过900万女性的多中心人群基础研究
Yanrui BiYuan MaYing Gao
Research 30 December 2025
Article: 63
Sex differences in cardiac risk and kidney function: serum creatinine versus cystatin C
心脏风险和肾功能方面的性别差异：血清肌酐与胱抑素C的对比
Nicole L. De La MataJames A. HedleyJennifer S. Lees
Research 30 December 2025
Article: 62
The association of post-conization pregnancy with subsequent cervical lesions: evidence from a nationwide cohort in Sweden
锥切术后妊娠与后续宫颈病变的关联：来自瑞典全国队列研究的证据
Huan YiJimiao HuangJianguang Ji
Research 29 December 2025
Article: 61
Tibial periosteal distraction for ischemic leg ulcers: animal and clinical cohort study
胫骨骨膜牵张术治疗缺血性下肢溃疡：动物及临床队列研究
Peilin ZhouWenqiang WangQikai Hua
Research 28 December 2025
Article: 60
Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study
卡瑞利珠单抗联合紫杉醇和奈达铂对不可切除的晚期食管鳞癌的术前转化治疗：一项2期研究
Jinhong ZhuJinfeng ZhangJianqun Ma
Research 28 December 2025
Article: 59
Clustering of cardiometabolic risk factors, physical activity, digital exclusion, and depressive symptoms trajectories in adults aged 50years and older: findings from two prospective cohort studies
50岁及以上成年人心血管代谢风险因素聚集、身体活动、数字排斥及抑郁症状轨迹：两项前瞻性队列研究的发现
Xiaosheng DongJiaqiang XiaoChengchao Zhou
Research 28 December 2025
Article: 58
Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease
现实中符合心血管疾病阿司匹林一级预防试验资格的患者情况
Michael HolderDaniel R. MoralesBruce Guthrie
Research 27 January 2026
Article: 57
Polygenic risk score-guided personalized osteoporosis screening: a population-based study
基于多基因风险评分指导的个性化骨质疏松症筛查：一项基于人群的研究
Dongxue WangWen SunJianguang Ji
Research 14 January 2026
Article: 56
Urea cycle modulation by combined SGLT2 inhibitors and metformin
SGLT2抑制剂与二甲双胍联合用药对尿素循环的调节作用
Makoto HaradaJonathan AdamRui Wang-Sattler
Research 08 January 2026
Article: 55
Safety and neuroprotective efficacy of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo study
VCP抑制剂ML240在大型动物及人视网膜外植体中的安全性和神经保护功效：一项临床前离体研究
Ana-Cristina Almansa-GarcíaAngela ArmentoBlanca Arango-Gonzalez
Research 10 January 2026
Article: 54
Impact of an eight-week isocaloric vegan dietary intervention on hemogram parameters and lymphocyte subsets: a randomized-controlled trial
为期八周的等热量纯素饮食干预对血细胞参数和淋巴细胞亚群的影响：一项随机对照试验
Julian HerterFrieda StübingMaximilian Andreas Storz
Research 10 January 2026
Article: 53
Association between psychosocial factors and adverse effects of light-to-moderate ambient heat in patients with chronic diseases: results of the prospective cohort study CLIMATE-II
社会心理因素与轻至中度环境热对慢性病患者不良影响之间的关联：前瞻性队列研究CLIMATE-II的结果
Ingmar SchäferValentina PauckeDagmar Lühmann
Research 15 January 2026
Article: 52
Part of 1 collection:Climate change and human health
所属专题：气候变化与人类健康
Maternal infection during pregnancy and the risk of childhood cancer: a systematic review and meta-analysis
孕期母体感染与儿童期患癌风险：一项系统综述和荟萃分析
Loviisa MulanjeLara Kim BrackmannRajini Nagrani
Research 14 January 2026
Article: 51
Part of 1 collection:Carcinogens and human health
所属专题：致癌物与人类健康
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
分子肿瘤委员会中的补充生物标志物检测增加了可采取治疗措施的建议：一项针对658例患者的前瞻性真实世界研究
Alexander ScheiterSimon MellinKirsten Utpatel
Research 14 January 2026
Article: 50
Computer assisted verbal autopsy: comparing large language models to physicians for assigning causes to 6939 deaths in Sierra Leone from 2019–2022
计算机辅助口头尸检：对比大型语言模型与医生对塞拉利昂2019 - 2022年6939例死亡原因的判定
Richard WenAnteneh Tesfaye AssalifRashid Ansumana
Research 24 December 2025
Article: 49
Loss of Y chromosome and its implications in male amyotrophic lateral sclerosis: insights from the UK Biobank
Y染色体缺失及其在男性肌萎缩侧索硬化症中的影响：来自英国生物银行的研究见解
Wei-Ming SuQing-Qing DuanYong-Ping Chen
Research 24 December 2025
Article: 48
Part of 1 collection:Amyotrophic lateral sclerosis: latest advances and novel updates
所属专题：肌萎缩侧索硬化症：最新进展与新动态
Prenatal lipopolysaccharide exposure programs the early-life lung development by modulating mesenchymal fibroblasts in a time- and dose-dependent manner
产前脂多糖暴露通过调节间充质成纤维细胞以时间和剂量依赖性方式来影响早期肺部发育
Ying DongStefan HadzicSaverio Bellusci
Research 22 December 2025
Article: 47
Life course socioeconomic trajectories and chronic disease risk in later life among 30,055 older adults across 27 European countries (the SHARE study)
27个欧洲国家30,055名老年人生命历程中的社会经济轨迹与晚年慢性疾病风险（基于SHARE研究）
Taymara C. AbreuJoline W. J. BeulensJoreintje D. Mackenbach
Research 20 December 2025
Article: 46
Part of 1 collection:Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题：健康老龄化与长寿：预防医学与风险因素的作用
Validation of a novel patient-reported measure of the burden of digital care in diabetes
由糖尿病患者报告的数字化护理负担新型测评工具的验证
Misk Al ZahidyJennifer L. RidgewayVictor M. Montori
Research 20 December 2025
Article: 45
Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa
撒哈拉以南非洲地区无症状至中度 COVID-19 患者长期 SARS-CoV-2 免疫应答的决定因素
Víctor L. de RiojaOdin GoovaertsGemma Moncunill
Research 14 January 2026
Article: 44
Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial
卡瑞利珠单抗联合阿帕替尼治疗中国局灶性晚期或转移性放射性碘难治性分化型甲状腺癌：一项探索性开放标签单臂试验
Xin ZhangDi SunYansong Lin
Research 18 December 2025
Article: 43
Urinary polyphenol signature of the Mediterranean diet is associated with lower cardiovascular disease risk: the PREDIMED trial
地中海饮食的尿液多酚特征与心血管疾病风险较低相关：PREDIMED 试验
Inés Domínguez-LópezPolina GalkinaRosa M. Lamuela-Raventós
Research 18 December 2025
Article: 42
Meta-analysis and external validation of a risk model for gastrointestinal bleeding after percutaneous coronary intervention
经皮冠状动脉介入治疗后胃肠道出血风险模型的荟萃分析及外部验证
Hualong MaCong PengQiaohong Yang
Research 18 December 2025
Article: 41
DNA methylation-based clocks, tobacco smoking, and lung cancer risk
基于DNA甲基化的生物钟、烟草吸烟与肺癌风险
Ricardo Cortez Cardoso PenhaJustina Ucheojor OnwukaMattias Johansson
Research 17 December 2025
Article: 40
Part of 1 collection:Carcinogens and human health
所属专题：致癌物与人类健康
Risk and protective factors associated with brain grey matter patterns in a population-based cohort of cognitively unimpaired 70years old
认知功能未受损的70岁老年人基于人口的队列中，与大脑灰质模式相关的风险和保护因素
Giulia LorenzonAnna MarsegliaEric Westman
Research 17 December 2025
Article: 39
Part of 1 collection:Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题：健康老龄化与长寿：预防医学和风险因素的作用
Street view-derived city built environment and vulnerability to temperature extremes: a nationally representative population-based cohort study
基于街景图像的城市建成环境与极端温度脆弱性：一项全国代表性人口队列研究
Wanzhou WangChao YangLuxia Zhang
Research 16 December 2025
Article: 38
Part of 1 collection:Climate change and human health
所属专题：气候变化与人类健康
A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity
针对病毒变异株的灭活严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）疫苗加强针可维持保护性体液免疫和细胞免疫
Constanza MéndezLinmar Rodríguez-GuilarteSusan M. Bueno
Research 15 December 2025
Article: 37
Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib
达格列净通过AMPKα-PPARα轴减轻舒尼替尼诱导的心脏毒性，并增强肾细胞癌对舒尼替尼的敏感性
Shi-yu HuangMin HuLei Wang
Research 15 December 2025
Article: 36
Network dysfunction underlying verbal fluency deficits in newly diagnosed epilepsy: a resting-state fMRI functional connectivity study
新诊断癫痫患者言语流畅性缺陷背后的网络功能障碍：一项静息态功能磁共振成像功能连接研究
Fangzhou LiuPing JiangLing Liu
Research 13 December 2025
Article: 35
Part of 1 collection:Epilepsy: Seizure prevention, treatment, and epidemiology
所属专题：癫痫：癫痫发作的预防、治疗和流行病学
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case–control study
基于广西新生儿地中海贫血基因组图谱计划开展的家庭三联体/四联体分析
Coraline DubotIsabelle Ray-CoquardFlorence Joly
Research 12 December 2025
Article: 34
Family trios/quartets analysis based on the Newborn Genomic Atlas for Thalassemia project in Guangxi
非上皮性卵巢癌幸存者的长期生活质量：TMRG-GINECO-Vivrovaire罕见肿瘤病例对照研究
Wei WeiChunrong GuiBaoheng Gui
Research 12 December 2025
Article: 33
Hyperuricemic persons use more analgesics than normouricemic—is asymptomatic hyperuricemia really asymptomatic?
高尿酸血症患者比血尿酸正常者使用更多镇痛药——无症状性高尿酸血症真的“无症状”吗？
Janis TimsansJenni Emilia KauppiMarkku Kauppi
Research 11 December 2025
Article: 32
Social isolation, loneliness, and multi-system medical conditions: phenome-wide association and disease-trajectory analyses
社会孤立、孤独感与多系统医学病症：全表型组关联分析及疾病轨迹研究
Tingshan DuanZhi CaoChenjie Xu
Research 10 December 2025
Article: 31
Digital marketing techniques within online food retail platforms: a scoping review
在线食品零售平台中的数字营销技巧：一项范围综述
Adyya GuptaCatherine E. HugginsAnna Peeters
Research 10 December 2025
Article: 30
Dramatic increases in redundant publications in the Generative AI era
生成式人工智能时代冗余出版物数量急剧增加
Danny MaupinTulsi SuchakMatt Spick
Research 09 December 2025
Article: 29
Cardiovascular risk burden and guideline-recommended lipid and blood pressure goals in an Italian Cohort: findings from the HUMTELEMED web-based platform
意大利人群心血管风险负担及指南推荐的血脂和血压目标达成情况：HUMTELEMED网络平台的发现
Matteo LandolfoAlessandro GezziRiccardo Sarzani
Research 09 December 2025
Article: 28
Part of 1 collection:Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题：健康老龄化与长寿：预防医学及风险因素的作用
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial
Janus激酶1/2抑制剂KL130008治疗活动性类风湿关节炎的有效性和安全性：一项随机、双盲、安慰剂对照的II期试验
Yue ChengHonghu TangYi Liu
Research 09 December 2025
Article: 27
Risk stratification for endometrial cancer: independent and joint effects of polygenic risk score and body mass index in 129,829 UK Biobank participants
子宫内膜癌的风险分层：英国生物银行129,829名参与者中多基因风险评分和体重指数的独立及联合效应
Xuemin WangLaure DossusTracy A. O’Mara
Research 10 February 2026
Article: 26
Maternal probiotics intake during pregnancy and exclusive colostrum breastfeeding are associated with a reduced risk of neonatal jaundice
孕期摄入益生菌及纯母乳喂养初乳与新生儿黄疸风险降低相关
Bekalu Kassie AlemuChi Chiu WangYao Wang
Research 08 December 2025
Article: 25
Hepatic steatosis in postmenopausal women is characterized by distinct serum extracellular vesicle proteomic signatures
绝经后女性脂肪肝具有独特的血清细胞外囊泡蛋白质组特征
Patrick PirrotteBrooke LovellJohanna K. DiStefano
Research 07 December 2025
Article: 24
Global, regional, and national temporal trends in the prevalence of environmental heat and cold exposure among older adults aged 60–99 years, 1990–2021: an age-period-cohort analysis based on the Global Burden of Disease Study 2021
基于2021年全球疾病负担研究，对1990 - 2021年60 - 99岁老年人环境热暴露和冷暴露患病率的全球、区域和国家时间趋势分析：一项基于年龄 - 时期 - 队列模型的分析
Shenghao XuJing WangJianlin Xiao
Research 07 December 2025
Article: 23
Part of 1 collection:Climate change and human health
所属专题：气候变化与人类健康
Cyclophilin B deficiency enhances myocardial energy synthesis and protects against heart failure in preclinical models
亲环蛋白B缺乏可增强心肌能量合成，并在临床前模型中预防心力衰竭
Xiao ZongXierenayi TudiRong Tao
Research 07 December 2025
Article: 22
Part of 1 collection:Cardiomyopathy and cardiac arrhythmias
所属专题：心肌病与心律失常
Normobaric hyperoxia for intracerebral hemorrhage: a randomized clinical trial
常压高氧治疗脑出血：一项随机临床试验
Zhiying ChenJiayue DingRan Meng
Research 07 December 2025
Article: 21
Nationwide trends in pediatric hospitalizations for eating disorders in France between 2013 and 2022: a retrospective study using the national health insurance database
Emmanuelle LogeaisFrançoise TroussierLilia Khendek
2013 - 2022年法国因进食障碍住院的儿科患者全国趋势：一项使用国家健康保险数据库的回顾性研究
Research 05 December 2025
Article: 20
Part of 1 collection:Child and adolescent psychiatry
所属专题：儿童与青少年精神病学
Self-management of vaginal pessaries for pelvic organ prolapse: multi-method process evaluation, linked to the TOPSY randomised controlled trial
盆腔器官脱垂阴道子宫托自我管理：与TOPSY随机对照试验相关的多方法过程评估
Carol BuggeMelanie Dembinskythe TOPSY team
Research 05 December 2025
Article: 19
Large-scale plasma proteomics reveals bidirectional associations between sleep patterns and inflammatory bowel disease: a prospective cohort study
大规模血浆蛋白质组学研究揭示睡眠模式与炎症性肠病之间的双向关联：一项前瞻性队列研究
Kaixing LeYaru LiuZhigang Liu
Research 05 December 2025
Article: 18
Association between socioeconomic status and diabetic retinopathy in individuals with type 1 diabetes: a systematic review and meta-analysis
1型糖尿病患者社会经济地位与糖尿病视网膜病变之间的关联：一项系统综述和荟萃分析
Fernando Sebastian-VallesSergio Núñez de Arenas-ArroyoJulia Martínez-Alfonso
Review 05 December 2025
Article: 17
Patterns of disparity: age and socioeconomic differences in women’s smoking and quitting outcomes in Great Britain
差异模式：英国女性吸烟及戒烟结局的年龄和社会经济差异
Sarah E. JacksonCaitlin NotleySharon Cox
Research 10 February 2026
Article: 16
Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression
SWI/SNF复合体中的基因组致病性改变通过下调STING表达损害中国KRAS突变型非小细胞肺癌患者的免疫治疗效果
Lingling GaoJie JiangXuchao Zhang
Research 03 December 2025
Article: 15
Residential radon exposure and incident myocardial infarction and stroke risks in the All of Us Research Program
“我们所有人”研究项目中住宅氡暴露与心肌梗死和卒中发病风险的关系
Jiajun LuoZhihao JinBriseis Aschebrook-Kilfoy
Research 03 December 2025
Article: 14
Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet and cardiovascular disease and arrhythmias
用于延缓神经退行性变的地中海饮食-终止高血压膳食疗法干预措施（MIND）与心血管疾病及心律失常的关系
Pei QinFrederick K. HoJill P. Pell
Research02 December 2025
Article: 13
Part of 1 collection: Cardiomyopathy and cardiac arrhythmias
所属专题：心肌病与心律失常
KoMethylNet: a novel epigenetic clock based on neural network analysis of DNA methylation data and epigenetic age acceleration in a Korean population
KoMethylNet：基于神经网络分析DNA甲基化数据的新型表观遗传时钟及韩国人群的表观遗传年龄加速研究
Dabin YunKwangyeon OhNan Song
Research 03 December 2025
Article: 12
Part of 1 collection: Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题：健康老龄化与长寿：预防医学及风险因素的作用
Sleep and physical activity trade-offs and dementia risk: a prospective cohort study in UK Biobank participants
睡眠与体力活动的权衡与痴呆风险：英国生物样本库参与者的一项前瞻性队列研究
Stephanie YiallourouLachlan CribbMatthew P. Pase
Research 03 December 2025
Article: 11
Part of 1 collection: Sleep and mental health
所属专题：睡眠与心理健康
Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer
肠道微生物组与脂质代谢的整合揭示十五烷酸对膀胱癌的抗癌作用
Ya-Ting ChenJing SuiEvan Yi-Wen Yu
Research 03 December 2025
Article: 10
Part of 1 collection: Gut microbiota: New treatments of human disease
所属专题：肠道微生物群：人类疾病的新疗法
A social determinants-based county-level cardiovascular mortality index to identify high-risk counties in the USA
基于社会决定因素的美国县级心血管疾病死亡率指数，用于识别高风险县
Anqi ZhuBibhas ChakrabortyTazeen H. Jafar
Research 02 December 2025
Article: 9
HIV infection and immunosenescence: challenges and intervention strategies
HIV感染与免疫衰老：挑战与干预策略
Junyan JinQianqian XuBin Su
Review 02 December 2025
Article: 8
Part of 1 collection: Healthy aging and longevity: the role of preventive medicine and risk factors
所属专题：健康老龄化与长寿：预防医学与风险因素的作用
Machine learning-based prediction of short-term outcomes in aneurysmal subarachnoid hemorrhage: a multicenter study integrating clinical and inflammatory indicators
基于机器学习的动脉瘤性蛛网膜下腔出血短期预后预测：一项整合临床与炎症指标的多中心研究
Weichong ZhouCong PengHui Shi
Research 29 November 2025
Article: 7
The effectiveness and safety of a mobile application-based self-regulation intervention to support weight loss among adults living with obesity: a large-scale pragmatic randomised controlled trial
基于移动应用程序的自我调节干预措施在支持肥胖成年人减重方面的有效性与安全性：一项大规模实用性随机对照试验
Paul DoodyGina M. WrenPaul Aveyard
Research 29 November 2025
Article: 6
Part of 1 collection: Weight loss interventions and their health impacts
所属专题：减重干预措施及其对健康的影响
Adiposity and the first-onset of diagnosed mental illnesses: a population-based cohort study of 10 million UK adults
脂肪堆积（肥胖程度）与首次确诊精神疾病的关系：一项基于1000万英国成年人的队列研究
Xue DongPaul AveyardMin Gao
Research 29 November 2025
Article: 5
Efficacy of standard care versus acoustic therapy on acute tinnitus in idiopathic sudden sensorineural hearing loss: a randomized controlled trial
标准治疗与声治疗对特发性突发性感音神经性听力损失伴急性耳鸣的疗效对比：一项随机对照试验
Xinyi WangKe QiuYu Zhao
Research 28 November 2025
Article: 4
Trends and socio-economic inequalities in overweight- and obesity-related premature cardiovascular disease mortality in Australia
澳大利亚超重与肥胖相关过早心血管疾病死亡的趋势及社会经济不平等状况
Tim Adair
Research 29 January 2026
Article: 3
Assessing the impact of maternal blood pressure during pregnancy on perinatal health: a wide-angled Mendelian randomization study
评估孕期母体血压对围产期健康的影响：一项广角孟德尔随机化研究
Fernanda Morales-BersteinAna Gonçalves-SoaresMaria-Carolina Borges
Research 14 January 2026
Article: 2
Part of 1 collection:Diagnosis and management of gestational diabetes
所属专题：妊娠期糖尿病的诊断与管理
Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain
胰高血糖素样肽-1受体激动剂用于减重的使用率及使用意愿：一项针对英国人群的研究
Sarah E. JacksonJamie BrownLion Shahab
Research 08 January 2026
Article: 1
Part of 1 collection: Weight loss interventions and their health impacts
所属专题：减重干预措施及其对健康的影响
临床1期
2026-04-01
·有驾
昂利康是方南平家族实际控制的深交所主板上市民营制药企业，国家级高新技术企业，国内领先的化学原料药及制剂一体化企业，是全球最大的 α- 酮酸原料药生产基地，国内口服头孢类抗生素核心供应商，核心品种头孢克洛缓释片、苯磺酸左氨氯地平片在细分市场市占率稳居前列，构建了 “中间体 — 原料药 — 制剂” 垂直一体化的全产业链护城河。公司正处于从传统仿制药企向 “仿创结合” 创新型药企转型的关键期，在巩固传统原料药与制剂基本盘的同时，通过授权引进与自主研发双轮驱动，布局肿瘤 ADC 药物、双靶点激动剂等创新药管线，同时切入宠物药、植物源胆固醇等高毛利特色赛道，打造多轮驱动的增长格局。2025 年公司业绩实现强劲反转，全年预计归母净利润 1.10-1.38 亿元，同比增长 36.93%-71.78%，扣非净利润同比最高翻倍增长，业绩拐点明确。2026 年 4 月 1 日，受 2025 年业绩大幅预增、创新药管线临床进展推进、11.6 亿元定增募资助力创新转型、医药板块整体回暖等多重利好催化，公司股价强势涨停 10.01%，报收 34.88 元，总市值约 70.36 亿元，当日成交额 7.27 亿元，换手率 11.71%，较前 5 个交易日成交额放大 3 倍，增量资金大举进场，股价成功突破近 6 个月平台压力位。整体判断，标的是典型的 “传统业务盈利韧性充足、业绩拐点明确、创新药转型打开长期成长天花板” 的医药成长标的，短期股价受业绩预增与创新药主题情绪催化，中长期投资价值核心在于传统制剂与原料药业务的盈利修复持续性，以及创新药管线临床进展、宠物药与高端中间体新业务的放量节奏。公司当前动态市盈率（TTM）约 67.93 倍，估值已反映市场对其创新转型的乐观预期，估值溢价与研发风险并存，适合高风险偏好的成长型投资者、医药主题投资者重点关注，稳健型投资者可等待创新药临床数据验证或估值回调后再择机布局。
一、公司核心标识与基本盘
二、主营业务与战略定位：垂直一体化筑基，仿创结合谋远，多赛道布局打开成长天花板
公司核心战略定位为巩固并强化 “中间体 — 原料药 — 制剂” 垂直一体化产业链优势，在口服头孢、α- 酮酸、心血管制剂等传统优势领域持续夯实龙头地位，通过集采中标与渠道下沉实现制剂业务的持续放量；坚定推进 “仿制药 — 改良型新药 — 创新药” 的研发战略升级，通过 “自主研发 + 授权引进” 双轮驱动，快速切入肿瘤、代谢类疾病创新药赛道；积极拓展宠物药、植物源胆固醇等高毛利特色业务，最终打造 “传统业务稳盘、创新业务突破、特色业务补位” 的多轮驱动增长格局，实现从传统仿制药企向创新型综合制药企业的跨越。
（一）核心业绩基石：原料药与制剂一体化业务 —— 基本盘稳固，盈利韧性充足
原料药与制剂一体化是公司的核心竞争优势，也是公司经营的基本盘，通过全产业链布局，公司实现了从核心中间体到原料药再到终端制剂的全流程自主可控，在成本控制、质量稳定性、集采竞标中具备显著的竞争优势。
原料药业务：细分赛道全球龙头，客户壁垒深厚公司原料药业务核心聚焦 α- 酮酸、口服头孢类两大优势领域，同时布局心血管、麻醉类原料药，是全球 α- 酮酸原料药绝对龙头，产能与市占率均位居全球第一，与全球肾病治疗龙头费森尤斯卡比签订了长期独家供应协议，客户粘性极强，合作关系稳定。口服头孢类原料药采用行业领先的酶法生产工艺，较传统化学合成工艺成本降低 20% 以上，环保优势显著，产品供应国内头部制剂企业，同时出口至欧盟、东南亚等海外市场，2025 年海外出口订单同比增长超 30%。公司原料药产品均通过国家 GMP 认证，核心品种获得欧盟 CEP、美国 FDA 认证，具备国际化供应能力，在全球原料药产业链重构的背景下，海外市场拓展空间持续打开。
化学制剂业务：集采中标放量，产品矩阵持续丰富制剂业务是公司第一大收入来源，也是核心利润支柱，产品覆盖抗感染、心血管、肾病、麻醉、泌尿等多个治疗领域，拥有超过 60 个药品生产批文，其中 20 余个品种通过国家仿制药一致性评价，在集采竞标中具备显著优势。
核心品种市占率领先：头孢克洛缓释片（帅先）是国内首家通过一致性评价的品种，市占率稳居行业第一；苯磺酸左氨氯地平片（左益）是国内心血管领域的核心品种，在基层医疗市场市占率位居前三；复方 α- 酮酸片通过集采中标后，市场份额快速提升，成为公司制剂业务新的增长极。
集采中标持续放量：公司多个核心品种在国家及地方集采中成功中标，凭借一体化成本优势，在降价的同时仍保持了合理的利润空间，中标后通过渠道下沉快速实现销量翻倍增长，带动制剂业务收入与利润持续提升。
新品获批持续补充：近年公司利丙双卡因乳膏、普瑞巴林胶囊、吸入用七氟烷等多个新品获批上市，覆盖麻醉、皮肤科、神经类等多个领域，进一步丰富了产品矩阵，为制剂业务增长提供了持续动力。
（二）核心增长引擎：创新药研发与管线布局 —— 转型核心载体，打开长期成长天花板
创新药研发是公司战略转型的核心方向，公司通过 “自主研发 + 全球授权引进” 双轮驱动，快速搭建创新药研发管线，重点布局肿瘤、代谢性疾病两大高景气赛道，实现从仿制药企向创新药企的跨越。
授权引进管线：肿瘤创新药进入临床阶段公司通过与上海亲合力生物等国内顶尖创新药研发企业合作，获得了两大核心创新药在中国区的独家权益，快速切入高壁垒的肿瘤创新药赛道：
ALK-N001（QHL-1618）：肿瘤微环境激活型 ADC 药物，靶向叶酸受体 α（FRα），主要用于治疗卵巢癌、非小细胞肺癌等实体瘤，相较于同类产品具备更高的安全性与有效性，2025 年 4 月已获得 CDE 批准进入 I 期临床试验，是公司创新药转型的核心标杆品种，目前临床进展顺利，预计 2026 年下半年读出 I 期临床数据。
ALK-N002（IMD-1005）：靶向 CD47 的遮罩型抗体药物，可有效规避传统 CD47 抗体的血液毒性，在血液瘤与实体瘤治疗中具备广阔的应用前景，目前处于 IND 申报准备阶段，预计 2026 年下半年获批进入临床试验。
自主研发管线：代谢类创新药进入 II 期临床公司自主研发的 1 类新药ALG-001，是 GLP-1/GIP 双靶点激动剂，对标礼来替尔泊肽（Mounjaro），用于 2 型糖尿病与肥胖症治疗，目前已获得 CDE 批准进入 II 期临床试验，2026 年将启动中美同步临床，潜在市场空间超百亿元。该品种在临床前研究中展现出优异的降糖、减重效果与安全性，具备成为同类最佳（Best-in-Class）的潜力，未来若临床进展顺利，有望成为公司首个商业化的创新药品种，同时具备海外 license-out 的合作潜力。
仿制药与改良型新药管线：持续补充业绩增量公司在聚焦创新药研发的同时，持续推进高端仿制药与改良型新药的研发，目前恩格列净片、达格列净片、利拉鲁肽注射液等 3 个重磅仿制药处于 BE 试验阶段，预计 2026-2027 年陆续申报上市，覆盖糖尿病、肥胖症等高增长赛道，将为公司带来持续的业绩增量。同时，公司布局多个缓控释、口溶膜等高端制剂改良型新药，进一步提升产品的技术壁垒与盈利水平。
（三）特色新增长曲线：高端中间体与宠物药业务 —— 高毛利蓝海赛道，打造第二增长曲线
在巩固传统主业、推进创新药转型的同时，公司积极布局高毛利、高壁垒的蓝海赛道，打造新的业绩增长极，降低对传统仿制药业务的依赖。
植物源胆固醇业务：全球独家技术，毛利率超 70%公司控股子公司科瑞生物是全球唯一实现植物源胆固醇规模化量产的企业，拥有完全自主知识产权，产品纯度达 99.5% 以上，打破了海外企业的技术垄断。植物源胆固醇是 mRNA 疫苗佐剂、高端化妆品、甾体药物的核心原材料，随着全球 mRNA 疫苗产业的快速发展，市场需求爆发式增长。该业务毛利率高达 70% 以上，2025 年上半年营收同比增长超 80%，已成为公司核心的利润增长点，未来随着产能释放与客户拓展，有望保持持续高速增长。
宠物药业务：先发优势显著，瞄准千亿蓝海市场公司积极布局快速增长的宠物医疗赛道，核心品种宠物用吸入用七氟烷已获批上市，填补了国内宠物麻醉药领域的空白，是国内首个获批的宠物专用七氟烷品种，凭借优异的产品质量与渠道优势，快速占领国内宠物麻醉药市场。同时，公司正在布局宠物慢病治疗、抗感染、驱虫等多个在研项目，搭建完善的宠物药产品矩阵。国内宠物药市场规模超千亿，年复合增长率超 20%，国产化率极低，公司凭借原料药制剂一体化优势，有望在宠物药赛道实现快速突破，打造新的长期增长引擎。
CDMO 业务：依托产能与技术优势，拓展新盈利模式公司依托完善的 GMP 生产体系与原料药研发技术优势，积极布局抗肿瘤、特色原料药 CDMO 业务，拟通过定增募资建设抗肿瘤原料药 CDMO 平台，为国内外创新药企提供从临床前研发到商业化生产的全流程 CDMO 服务。目前已与多家创新药企达成合作意向，未来 CDMO 业务将成为公司新的业绩增长点，同时与创新药研发业务形成协同效应。
（四）资本运作与产能扩张：定增募资助力转型，产能布局锁定长期增长
11.6 亿元定增募资，全力支撑创新药转型公司公告拟向特定对象发行股票募集资金不超过 11.6 亿元，全部用于 “创新药研发及产业化项目”，重点推进 ALK-N001、ALK-N002 等核心创新药管线的临床研究、产业化基地建设，以及 GLP-1 双靶点激动剂的临床研发。本次定增实控人方南平承诺以现金方式认购不低于 1 亿元，锁定期 18 个月，彰显了对公司创新转型战略的坚定信心与长期发展前景的认可。定增若顺利实施，将为公司创新药研发提供充足的资金保障，大幅加速创新转型进程。
产能扩张与升级，夯实长期发展基础公司持续推进产能布局与升级，拟投资 3.89 亿元建设 “年产 8000 吨阿莫西林、2000 吨氨苄西林项目”，将酶法工艺优势延伸至青霉素类抗感染领域，进一步强化抗感染产业链的成本优势；新建高端口服固体制剂车间已于 2025 年第一季度投产，可支持缓释、肠溶等高壁垒剂型的规模化生产，大幅提升高端制剂产能；α- 酮酸原料药扩产项目稳步推进，新增 50 吨 / 年产能，将进一步巩固全球龙头地位，满足全球市场需求增长。
三、财务表现与估值分析：业绩拐点明确，估值反映转型预期
公司财务呈现 \\“营收受原料药价格周期影响短期承压，但净利润在制剂放量、产品结构优化、费用管控下实现强劲反转，单季度业绩重回增长轨道；综合毛利率受集采与产品结构影响有所下滑，但高毛利业务占比提升带动毛利率边际修复；经营活动现金流健康充裕，资产结构稳健；当前估值处于较高水平，已脱离传统仿制药企的估值体系，核心反映了市场对其创新药转型的乐观预期，估值与创新药临床进展深度绑定”\\ 的核心特征。
（一）成长性与盈利性：业绩拐点正式确立，盈利质量持续改善
营收短期承压，单季度重回增长轨道公司营收规模受原料药价格周期波动影响，2025 年前三季度实现营收 10.55 亿元，同比下降 5.92%，核心源于头孢类原料药价格同比回落。但从单季度表现来看，公司业绩已出现明确反转，2025 年第三季度单季实现营收 3.31 亿元，同比增长 20.67%，环比增长 12.34%，重回双位数增长轨道，核心源于集采中标制剂品种持续放量、高毛利特色中间体业务高速增长，营收结构持续优化。随着制剂业务占比持续提升、原料药出口订单稳步增长，2026 年公司营收有望重回持续增长通道。
净利润实现强劲反转，盈利能力持续修复2024 年受集采降价、研发投入增加、资产减值计提等因素影响，公司归母净利润同比下滑，陷入业绩低谷；2025 年公司实现业绩强势反转，前三季度归母净利润 7768.99 万元，同比增长 55.59%，全年预计实现归母净利润 1.10-1.38 亿元，同比增长 36.93%-71.78%，扣非净利润同比最高实现翻倍增长，业绩拐点正式确立。盈利能力方面，公司综合毛利率从 2022 年的 57.38% 降至 2025 年前三季度的 38.78%，核心源于集采降价导致制剂业务毛利率有所回落，以及低毛利原料药业务占比阶段性提升。但随着高毛利的特色中间体、创新制剂业务收入占比持续提升，公司毛利率已出现边际修复，2025 年第三季度单季毛利率较上半年提升 2.1 个百分点，未来随着产品结构持续优化，毛利率有望稳步回升。同时，公司持续推进降本增效，销售费用率、管理费用率持续优化，研发费用精细化管控，净利率从 2024 年的低点持续修复，盈利能力持续改善。
（二）运营质量与财务健康度：现金流健康，资产结构稳健
经营现金流充裕，主业造血能力强劲2025 年前三季度公司经营活动现金流净额达 2.00 亿元，远超同期净利润规模，虽然同比略有下降，但绝对值仍保持高位，显示公司主业造血能力强劲，盈利质量优异。充足的经营现金流为公司创新药研发、产能扩张提供了坚实的内生资金支撑，降低了创新转型过程中的财务风险。
资产结构稳健，偿债能力充足截至 2025 年三季度末，公司资产负债率 37.51%，远低于化学制药行业 50% 的平均负债率水平，有息负债规模极小，货币资金超 4.5 亿元，流动比率、速动比率均处于安全警戒线以上，短期与长期偿债能力充足，财务结构极度稳健，无任何债务违约风险。即使 11.6 亿元定增未能顺利实施，公司现有资金储备也能支撑创新药管线的正常研发推进，财务安全垫极厚。
应收账款管理需持续关注截至 2025 年三季度末，公司应收账款规模达 4.87 亿元，应收账款周转天数升至 112 天，较上年同期有所拉长，核心源于制剂集采中标后，公立医院渠道回款周期较长。目前公司应收账款客户以公立医院、大型医药商业企业为主，坏账风险极低，但若回款周期持续拉长，将对公司运营资金造成一定占用，需持续关注应收账款周转情况。
（三）估值分析：估值反映转型预期，与临床进展深度绑定
以 2026 年 4 月 1 日涨停收盘价 34.88 元计算，公司对应总市值 70.36 亿元，动态市盈率（TTM）约 67.93 倍，市净率（LF）约 4.47 倍。
估值合理性判断：纵向对比，公司上市以来市盈率中枢约 35 倍，当前估值显著高于历史中枢，核心源于公司已从传统仿制药企向创新药企业转型，估值体系从仿制药的 PE 估值向创新药的管线估值切换。横向对比行业，传统化学仿制药企业平均 PE-TTM 约 25-30 倍，而具备创新药管线的转型药企平均 PE 约 50-80 倍，创新药企业 PS 估值约 8-10 倍，公司当前估值处于转型药企的合理区间，并未显著偏离行业水平。从业绩匹配度来看，以 2025 年业绩预告中值 1.24 亿元计算，当前对应 2025 年 PE 约 56.7 倍；若 2026 年公司净利润保持 50% 的增速，达到 1.86 亿元，对应 2026 年动态 PE 约 37.8 倍；若创新药管线临床进展顺利，估值将通过业绩增长与管线价值重估双重支撑；若创新药临床进展不及预期，估值将面临向传统仿制药企回归的回调压力。
估值提升与回归逻辑：若核心创新药 ALK-N001 I 期临床数据读出结果超预期、ALG-001 II 期临床顺利推进，市场将重新评估公司创新管线的价值，带动估值进一步提升；若创新药临床进展不及预期，或传统业务业绩增长失速，市场乐观预期将快速落空，估值将面临大幅回调，向传统仿制药企平均水平回归。
四、4 月 1 日涨停走势与盘口资金深度分析
2026 年 4 月 1 日，昂利康股价强势涨停 10.01%，报收 34.88 元，成功突破近 6 个月平台压力位，创近 8 个月新高，总市值 70.36 亿元，日内振幅 9.97%，成交额 7.27 亿元，换手率 11.71%，量比达 3.6，属于典型的业绩反转与创新药主题共振驱动的估值修复行情，具备扎实的基本面支撑与明确的成长逻辑。
（一）本次涨停的核心驱动因素
基本面核心催化：2025 年业绩大幅预增，拐点确定性增强公司发布 2025 年全年业绩预告，归母净利润同比增长 36.93%-71.78%，扣非净利润同比最高翻倍增长，业绩反转确定性极强，彻底消除了市场对公司持续经营的担忧，为股价上涨提供了坚实的基本面支撑，是本次涨停的核心基础。
成长逻辑催化：创新药管线进展顺利，定增助力转型公司核心创新药 ALK-N001 I 期临床进展顺利，预计 2026 年下半年读出临床数据，GLP-1 双靶点激动剂进入 II 期临床，创新药转型叙事持续强化；同时 11.6 亿元定增募资计划稳步推进，为创新药研发提供了充足的资金保障，市场对公司创新转型的信心持续增强，是本次涨停的核心成长催化。
行业催化：医药板块整体回暖，创新药主题情绪发酵近期医药板块整体持续回暖，创新药、化学制药板块集体走强，国家医保局明确慢病用药不纳入国谈降价范围，行业政策环境持续边际改善，市场风险偏好提升，资金持续回流医药板块，是本次涨停的重要行业催化。
资金催化：巨量放量，机构与游资同步进场公司当日成交额 7.27 亿元，较前 5 个交易日日均成交额放大 3 倍，量比达 3.6，主力资金净流入 1.32 亿元，占总成交额的 18.16%，机构与游资同步大举进场，形成了极强的做多合力，是本次股价涨停的直接推手。
（二）分时走势与盘口特征解读
分时走势：高开高走、直线拉升、早盘封死涨停，全天封板稳固公司当日以 31.72 元高开，较前一交易日收盘价高开 0.53%，开盘后无回踩，买盘资金持续涌入，股价直线拉升，开盘仅 30 分钟涨幅便突破 7%；9:58 分，资金加速进场，股价触及 10.01% 涨停板，短暂开板完成换手后，于 10:15 前牢牢封死涨停板 34.88 元，直至收盘未再开板，全天封板结构极为稳固，多头力量占据绝对主导。日内振幅 9.97%，单日换手率 11.71%，全流通筹码完成了充分交换，前期套牢盘与长线获利盘逢高了结，机构、游资与散户资金同步进场接力，新主力持仓成本集中在 31.72-34.88 元区间，与当前收盘价差距较小，后续股价上行具备坚实的筹码基础。
量能与换手率：健康放量，筹码结构持续优化
成交额与量比：当日成交额 7.27 亿元，创下近 6 个月单日成交额新高，量比达 3.6，远超正常水平，较前几个交易日显著放量，增量资金进场信号明确，量价配合健康，无量价背离特征。
换手率：当日换手率 11.71%，属于中高换手涨停，对于小盘全流通标的而言，反映出市场多空博弈激烈，但多头力量占据绝对优势，场内筹码完成了充分的清洗，短期获利盘与套牢盘充分离场，大幅降低了后续股价上行的抛压。
盘口挂单与买卖力量：买方绝对主导，封单结构稳健
买卖五档挂单：涨停收盘时，买一档封单约 28.7 万股，对应资金约 1.0 亿元，占当日成交额的 13.8%，买二至买五档合计挂单超 8 万股，买盘挂单形成了极强的支撑；卖盘五档完全无挂单，涨停价抛压短期枯竭，场内筹码锁定性良好，封板有效性较高。
内外盘数据：当日盘口数据显示，外盘（主动买入）12.26 万手，内盘（主动卖出）9.43 万手，外盘显著大于内盘，与涨停走势完全匹配，真实反映了市场买方力量占据绝对主导，资金主动进场意愿极强。
（三）资金流向与龙虎榜情况
当日公司未登上龙虎榜，从资金流向数据来看，当日主力资金净流入 1.32 亿元，占总成交额的 18.16%，其中特大单净流入 8600 万元，大单净流入 4600 万元，散户资金净流出 4200 万元，北向资金净买入 1860 万元，呈现出机构、北向资金、游资协同做多的格局，无大额抛售资金，表明市场资金对公司业绩反转与创新转型逻辑高度认可，筹码快速向机构集中，为后续股价持续上涨提供了坚实的资金支撑。
（四）行情性质与后续走势预判
行情性质判定：本次涨停属于业绩反转与创新药主题共振驱动的估值修复行情，具备扎实的基本面支撑与明确的成长逻辑，并非纯题材炒作。公司业绩拐点明确，创新药管线临床进展顺利，转型逻辑清晰，本次涨停是市场对公司基本面反转与长期成长价值的重新认可，行情持续性核心取决于创新药临床进展与业绩增长的持续性。
后续走势预判：| 情景 | 概率 | 核心描述 || ---- | ---- | ---- || 乐观情景（55%）| 医药板块情绪持续发酵，公司发布创新药临床进展新动态，增量资金持续进场，公司股价次日高开 2%-4%，若早盘快速回封涨停，有望继续冲高挑战 40 元前期高点；若资金接力不足，将冲高回落，在 33.0-37.0 元区间宽幅震荡 || 中性情景（40%）| 市场情绪出现分化，短线获利盘集中了结，公司无新的利好催化，股价次日平开或小幅高开，盘中宽幅震荡，消化当日获利盘，在 32.5-35.5 元区间震荡，等待 2025 年年报与一季报业绩催化 || 悲观情景（5%）| 医药板块集体回调，叠加公司无新的利好落地，高换手后资金接力不足，股价次日低开低走，回吐当日部分涨幅，在 31.0 元附近形成强支撑，开启震荡整理行情 |
五、核心看点与近期催化
业绩拐点确认，增长持续性可期公司 2025 年业绩实现大幅预增，单季度营收与净利润重回双位数增长，业绩拐点正式确立。随着集采中标制剂品种持续放量、高毛利特色中间体业务高速增长、原料药出口订单稳步提升，2026 年公司营收与净利润有望保持持续高速增长，为股价提供坚实的基本面支撑。2026 年 4 月底公司将发布 2025 年年报与 2026 年一季报，若业绩持续超预期，将成为股价上涨的核心催化。
创新药管线临床进展，打开估值天花板公司核心创新药 ALK-N001 预计 2026 年下半年读出 I 期临床数据，ALG-001 GLP-1 双靶点激动剂 II 期临床全面推进，若临床数据读出结果超预期，将彻底改变公司 “仿制药企” 的标签，创新管线价值将迎来重估，打开估值天花板。同时，ALK-N002 预计 2026 年下半年获批进入临床，管线持续兑现将进一步强化公司的创新药转型叙事。
定增募资落地，加速创新转型进程公司 11.6 亿元定增募资计划稳步推进，若顺利获批实施，将为创新药研发提供充足的资金保障，加速核心管线的临床研究与产业化进程，同时实控人参与认购将进一步稳定股权结构，彰显发展信心，定增获批与发行落地将成为重要的事件催化。
集采中标品种持续放量，新品上市补充增量公司复方 α- 酮酸片、头孢克洛缓释片等多个集采中标品种，正通过渠道下沉快速实现销量翻倍增长，带动制剂业务收入持续提升；同时，利丙双卡因乳膏、普瑞巴林胶囊等多个新品已获批上市，2026 年将进入放量期，恩格列净片、达格列净片等重磅仿制药预计 2026-2027 年陆续获批上市，为业绩增长提供持续的新动力。
特色新业务高速增长，打造第二增长曲线公司植物源胆固醇业务具备全球独家技术优势，毛利率超 70%，随着 mRNA 疫苗产业的快速发展，市场需求爆发式增长，该业务有望保持 80% 以上的年复合增速；宠物药业务首个品种已获批上市，多个在研品种持续推进，千亿蓝海市场将为公司带来全新的增长空间，新业务的持续放量将成为公司估值提升的重要催化。
行业政策环境持续边际改善国家医保局明确慢病用药不纳入国谈降价范围，集采规则持续优化，避免仿制药价格恶性竞争，行业政策环境持续边际改善；同时，国家持续出台政策鼓励医药创新与原料药制剂一体化发展，公司业务模式与发展战略高度契合政策导向，将持续受益于行业政策红利。
六、核心投资逻辑与风险提示
（一）核心投资逻辑（业绩修复与创新转型）
“集采风险出清 + 新品放量” 的业绩修复逻辑核心逻辑是：公司传统核心制剂品种受集采冲击的影响已基本消化，业绩底部已现，随着复方 α- 酮酸片等新中标集采品种持续放量，以及多个新品获批上市，制剂业务收入与利润将重回持续增长轨道；同时，高毛利的特色中间体业务高速增长，带动公司整体盈利能力持续修复，业绩增长的确定性极强。
“创新药管线价值重估” 的成长转型逻辑核心逻辑是：公司通过 “自主研发 + 授权引进” 双轮驱动，快速搭建了覆盖肿瘤、代谢类疾病的创新药管线，核心品种已进入临床阶段，彻底摆脱了传统仿制药企的增长瓶颈。若核心创新药临床进展顺利，公司将完成从仿制药企向创新药企的跨越，管线价值将迎来重估，彻底打开长期成长天花板。
“垂直一体化 + 独家技术” 的护城河逻辑核心逻辑是：公司 “中间体 — 原料药 — 制剂” 垂直一体化的全产业链布局，在成本控制、质量稳定性、集采竞标中具备显著的竞争优势，在 α- 酮酸、口服头孢领域形成了深厚的龙头壁垒；同时，子公司科瑞生物的植物源胆固醇全球独家技术，具备极高的技术壁垒与盈利水平，这种一体化优势与独家技术，为公司的创新转型提供了稳定的现金流与安全垫，降低了转型过程中的经营风险。
“多赛道布局” 的第二增长曲线逻辑核心逻辑是：公司在巩固传统主业的同时，积极布局宠物药、CDMO 等高增长、高毛利的蓝海赛道，形成了多轮驱动的增长格局。国内宠物药市场规模超千亿，国产化率极低，CDMO 行业保持高速增长，公司凭借原料药制剂一体化优势，有望在这些赛道实现快速突破，打造全新的业绩增长引擎，进一步提升长期估值水平。
（二）必须正视的核心风险与挑战
创新药研发失败的核心风险创新药研发具有周期长、投入大、失败率高的特点，公司核心创新药 ALK-N001、ALG-001 均处于临床阶段，最终能否成功上市存在巨大不确定性。若临床研究中出现安全性问题、有效性未达预期，或研发进度显著慢于预期，将导致前期巨额研发投入无法收回，同时市场对公司的转型预期将彻底落空，股价面临大幅回调的风险，这是公司转型过程中的核心风险。
集采降价与行业竞争加剧风险医药行业集采已进入常态化阶段，公司现有及未来上市的仿制药品种，仍可能面临国家或地方集采的降价压力，若中标价格大幅低于预期，将直接影响产品的毛利率与盈利能力。同时，仿制药赛道同质化竞争激烈，若竞争对手推出同类产品，将导致公司市场份额下滑，侵蚀利润空间。
原料药价格波动风险公司原料药业务营收占比接近 40%，原料药价格受市场供需、环保政策、原材料成本等多重因素影响，周期性波动显著。若头孢类、α- 酮酸原料药价格出现大幅下跌，将直接影响公司的营收与利润水平，导致业绩增长不及预期。
估值过高的回调风险当前公司动态市盈率（TTM）近 68 倍，已大幅高于传统化学制药行业平均水平，估值中包含了极高的创新药转型成功预期。若创新药临床进展不及预期，或业绩增长失速，市场乐观预期将快速落空，股价将面临剧烈的估值回归，存在大幅下跌的风险。
定增实施的不确定性风险公司 11.6 亿元定增方案尚需深交所审核与证监会注册，能否顺利获批、何时获批、最终发行规模均存在不确定性。若定增未能顺利实施，将对公司创新药研发进度、产能扩张计划造成一定影响，同时市场对公司转型的信心也将受到冲击。
应收账款与经营现金流风险公司应收账款规模持续增长，周转天数有所拉长，若下游公立医院、医药商业企业回款进度不及预期，将导致公司运营资金占用增加，经营活动现金流持续承压，甚至出现坏账风险，对公司的生产经营与研发投入造成不利影响。
七、总结与策略建议
昂利康是一家在特色原料药与制剂一体化领域根基深厚，正全力向创新药赛道转型的高弹性医药成长标的。它用二十余年的时间构建了垂直一体化的全产业链护城河，在 α- 酮酸、口服头孢细分赛道做到了全球与国内龙头，又通过自主研发与授权引进，快速切入创新药蓝海赛道，同时布局宠物药、高端中间体等高增长领域，正在完成从传统仿制药企向创新型综合药企的跨越。投资它，本质上是投资其仿创结合战略的执行能力，以及创新药管线从临床到商业化的兑现潜力，是一场关于 “转型决心” 与 “研发兑现” 的长期博弈。
（一）分类型投资者策略建议
成长型与医药主题投资者当前是重点关注与配置的窗口期。公司业绩拐点明确，创新药管线临床进展顺利，转型逻辑清晰，同时受益于医药板块整体回暖。可以将其作为医药组合中具备转型弹性的成长标的进行配置，总仓位控制在医药板块持仓的 15% 以内。操作上，必须紧密跟踪三大核心信号：1）核心创新药的临床进展与数据读出结果；2）季度财报中制剂业务与特色中间体业务的增长情况；3）11.6 亿元定增的审批与发行进度。若创新药临床数据超预期，可继续加仓；若临床进展不及预期，需果断减仓离场。
价值成长型投资者建议等待更明确的验证信号后再择机介入。可以重点观察 2025 年年报与 2026 年一季报，确认业绩反转的持续性；同时等待创新药 I 期临床数据读出、II 期临床顺利推进的实质性突破，在估值出现一定回调、或创新药取得实质性进展时再考虑介入，避免在当前高估值下承担过多的研发不确定性风险。
行业配置型投资者可以将其作为化学制药板块中具备特色壁垒与转型弹性的标的进行小仓位配置，对冲组合中创新药龙头的波动风险。需注意公司市值规模较小，业绩与股价波动性显著大于行业龙头，需严格控制仓位占比。
短线交易者可以将其作为 “创新药”“GLP-1”“宠物药” 主题的短线博弈标的，密切关注医药板块轮动、创新药临床进展公告与市场情绪，进行快进快出的波段操作。需严格设置止盈止损线，若股价跌破 5 日线且无法快速收回，需果断离场，切忌将短线博弈做成长期投资。
已持仓的投资者
中长线持仓的成长型投资者：可继续持有底仓，核心跟踪创新药临床进展与季度业绩兑现情况，若创新药数据超预期、业绩持续高增，可在回调时适度加仓；若出现临床进展不及预期、业绩增长失速等负面信号，需适度减仓。
短线持仓的投资者：若持仓成本在 32 元以下，可继续持有观察，设置 32 元为止盈止损线；若持仓成本在 34 元以上，建议次日冲高适度减仓，锁定利润，规避短期回调与不确定性风险。
（二）关键观察节点与风险信号
核心观察节点（按优先级排序）
研发进展：创新药 ALK-N001 的 I 期临床数据读出时间及结果；ALG-001 的 II 期临床推进情况；ALK-N002 的 IND 申报与临床获批进度；仿制药品种的获批上市节奏。
业绩指标：2025 年年报与 2026 年一季报的营收、净利润增长情况；综合毛利率与净利率的修复趋势；高毛利特色中间体业务的收入占比与增速；集采中标品种的销量放量情况。
资本运作：11.6 亿元定增方案的审核、注册与发行进度；实控人认购情况；创新药管线的海外 license-out 合作进展。
业务拓展：宠物药新品的获批与市场推广情况；植物源胆固醇业务的产能释放与客户拓展进度；CDMO 业务的客户合作与订单落地情况。
核心风险信号（出现任一信号，需谨慎评估持仓）
核心创新药临床研究出现安全性问题、有效性未达预期，或研发进度大幅延期；
季度业绩增长不及预期，营收与净利润增速显著下滑，毛利率持续回落；
11.6 亿元定增方案未能通过监管审核，或发行规模大幅缩水；
核心品种纳入新一轮集采，中标价格大幅低于预期，盈利能力受到严重冲击；
医药板块情绪集体退潮，股价出现放量滞涨、大额资金出逃迹象。
八、重要风险提示与免责声明
重要风险提示：公司核心创新药管线尚处于临床阶段，研发周期长、投入大、失败率高，存在临床进展不及预期或研发失败的风险；公司当前动态市盈率（TTM）近 68 倍，估值已大幅高于行业平均水平，包含了极高的转型成功预期，若预期落空，股价将面临大幅回调的风险；医药行业集采常态化，公司产品可能面临降价压力，影响盈利能力；原料药价格受周期波动影响较大，可能导致公司业绩增长不及预期；11.6 亿元定增方案尚需监管审批，实施进度存在不确定性。投资者应充分评估自身风险承受能力，理性投资。
免责声明：本报告基于公开信息与数据撰写，仅为投资逻辑分析与市场参考，不构成任何投资建议。股市有风险，入市需谨慎。
100 项与 达格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 1型糖尿病 | 日本 | 2019-03-26 | |
| 慢性心力衰竭 | 欧盟 | 2012-11-11 | |
| 慢性心力衰竭 | 冰岛 | 2012-11-11 | |
| 慢性心力衰竭 | 列支敦士登 | 2012-11-11 | |
| 慢性心力衰竭 | 挪威 | 2012-11-11 | |
| 慢性肾病 | 澳大利亚 | 2012-10-22 | |
| 2型糖尿病 | 澳大利亚 | 2012-10-22 | |
| 心脏衰竭 | 澳大利亚 | 2012-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性心肌梗塞 | 临床3期 | 瑞典 | 2020-12-22 | |
| 急性心肌梗塞 | 临床3期 | 英国 | 2020-12-22 | |
| 急性Q波心肌梗死 | 临床3期 | 瑞典 | 2020-12-22 | |
| 急性Q波心肌梗死 | 临床3期 | 英国 | 2020-12-22 | |
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2020-04-01 | |
| 阵发性呼吸困难 | 临床3期 | 美国 | 2020-04-01 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2019-04-09 | |
| 射血分数降低的心力衰竭 | 临床3期 | 日本 | 2019-04-09 | |
| 射血分数降低的心力衰竭 | 临床3期 | 巴西 | 2019-04-09 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2019-04-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床4期 | 4 | Placebo+Dapagliflozin (Dapagliflozin Then Placebo) | 醖鹽壓網遞範廠繭鹽繭(衊鹽蓋憲獵鏇鏇壓築膚) = 齋憲選積壓網積築餘範 齋範襯鏇顧遞鹽願淵鏇 (窪簾廠製鑰醖製糧構遞, 鬱觸簾簾餘憲鏇淵餘膚 ~ 鹹膚繭鹽艱觸廠選選繭) 更多 | - | 2026-02-11 | ||
Placebo+Dapagliflozin (Placebo Then Dapagliflozin) | 醖鹽壓網遞範廠繭鹽繭(衊鹽蓋憲獵鏇鏇壓築膚) = 窪窪築餘顧壓鹹積觸積 齋範襯鏇顧遞鹽願淵鏇 (窪簾廠製鑰醖製糧構遞, 憲選醖鬱艱窪觸繭壓醖 ~ 獵襯襯鬱網廠觸鬱鏇淵) 更多 | ||||||
临床3期 | 56 | - | 积极 | 2026-02-02 | |||
Placebo | 觸簾構艱餘獵觸網網齋(壓蓋襯選鏇廠製夢顧鏇) = 遞範淵鏇願餘範選艱願 鹹鬱鏇蓋膚鑰觸簾淵繭 (繭鬱鏇觸製艱構衊淵餘 ) 更多 | ||||||
临床4期 | 18 | (Sitagliptin Group) | 鏇餘醖淵醖遞簾醖襯鏇(選糧積繭窪製獵範齋鑰) = 衊壓鹽夢鑰鹹餘衊製衊 觸膚遞鏇鹽鏇夢遞醖願 (鹽網簾壓獵簾齋獵鏇鹽, 膚鏇築網構醖蓋夢艱憲 ~ 網願衊選製鏇衊鬱壓顧) 更多 | - | 2026-01-28 | ||
(Dapagliflozin Group) | 鏇餘醖淵醖遞簾醖襯鏇(選糧積繭窪製獵範齋鑰) = 膚夢製糧遞窪廠窪鹽窪 觸膚遞鏇鹽鏇夢遞醖願 (鹽網簾壓獵簾齋獵鏇鹽, 艱糧鏇膚鑰願鹽淵鏇簾 ~ 鬱鑰壓願鹽網構餘餘繭) 更多 | ||||||
临床2期 | 73 | Zibo+Dapa (Zibo/Dapa) | 遞齋餘鏇鏇獵淵獵簾壓 = 鑰簾鏇膚醖遞觸蓋鑰網 鏇憲簾鑰鹽窪蓋簾鑰範 (夢淵餘鏇鑰齋壓蓋鏇膚, 構襯夢獵構衊艱膚繭鹹 ~ 鏇鬱繭齋顧憲憲壓醖夢) 更多 | - | 2026-01-20 | ||
placebo+Zibotentan (Zibo) | 遞齋餘鏇鏇獵淵獵簾壓 = 鬱艱壓網觸餘製壓餘顧 鏇憲簾鑰鹽窪蓋簾鑰範 (夢淵餘鏇鑰齋壓蓋鏇膚, 網簾製壓夢積餘夢醖網 ~ 網艱鑰築鑰網觸製簾齋) 更多 | ||||||
临床2期 | 52 | 齋淵顧窪鬱廠餘繭構糧(遞製壓範鬱繭餘積鬱範) = 鏇蓋壓窪遞廠範鬱糧餘 鏇鑰獵築製夢觸壓鹽網 (鏇鬱範繭遞鏇膚範範壓, -7.14 ~ -1.24) | 积极 | 2025-12-12 | |||
临床3期 | 2型糖尿病 Gal-3 | 14,530 | 積廠繭淵鑰築鹽夢鹹範(觸觸夢築壓構衊艱選膚) = 窪廠選積壓齋壓淵鬱衊 選獵襯鏇鹹願窪顧鬱網 (網餘遞襯齋襯淵醖襯憲, 11.9 ~ 18.4) | 积极 | 2025-12-01 | ||
临床4期 | 2,072 | 鏇簾餘襯蓋獵餘壓膚選(衊壓遞繭艱簾觸艱齋簾) = 鏇選糧鬱網簾蓋鑰網簾 醖構淵築廠構憲顧範齋 (獵齋膚製膚鏇窪膚膚鹹 ) 更多 | 积极 | 2025-11-28 | |||
临床2期 | 324 | 製壓簾網壓製構構選醖(淵窪構夢餘簾願築衊選) = 淵壓窪襯網壓顧壓範選 醖窪製餘鏇顧餘淵網齋 (構網糧鬱憲齋夢襯範願 ) | 积极 | 2025-11-26 | |||
临床3期 | 2,401 | 窪糧製鹹餘顧構夢蓋襯(繭膚淵範選壓繭構襯壓) = 蓋簾網網範醖淵積糧獵 餘鏇蓋築網襯簾築憲壓 (餘積蓋窪艱艱顧膚簾廠 ) 更多 | 不佳 | 2025-11-18 | |||
Placebo | 窪糧製鹹餘顧構夢蓋襯(繭膚淵範選壓繭構襯壓) = 糧壓糧鏇遞觸膚鹹製網 餘鏇蓋築網襯簾築憲壓 (餘積蓋窪艱艱顧膚簾廠 ) 更多 | ||||||
临床2期 | 368 | 選願蓋鬱夢製衊獵艱觸(廠襯夢觸鏇壓鹽選選築) = 衊艱鏇範築鬱鏇鏇憲齋 壓選選觸選觸鬱膚襯鏇 (窪齋獵積蓋製鹽餘憲鏇, -9.54， ~ 0.44) 更多 | 积极 | 2025-11-08 | |||
選願蓋鬱夢製衊獵艱觸(廠襯夢觸鏇壓鹽選選築) = 廠壓網夢製築網壓醖鏇 壓選選觸選觸鬱膚襯鏇 (窪齋獵積蓋製鹽餘憲鏇, -17.17， ~ 9.45) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用